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CHAPTER ONE 
GENERAL INTRODUCTION 
“This marriage of good science and good 
therapeutics with all its attending benefits should 
give heart, confidence, persistence, and 
dedication to those who travel the road of 
experimental therapeutics.” 
  
 - William R. Martin, 1979 
 British Journal of Clinical 
 Pharmacology  
 
 
 The medicinal and troublesome properties of opium and opium alkaloids have 
been known for thousands of years (Levinthal, 1985). More than 160 years of research 
following the isolation of morphine, which included seminal work in identifying opioid 
binding sites (Goldstein et al., 1971; Lord et al., 1977; Pert and Snyder, 1973), and 
characterizing the in vivo effects of various opioid agonists and antagonists (Kosterlitz 
and Robinson, 1958; Martin and Gorodetzky, 1965; McClane and Martin, 1976), it was 
determined that the therapeutic and unwanted effects of these ligands are mediated 
through the µ-opioid receptor. Today, µ-opioid receptor agonists, such as morphine, 
oxycodone, codeine, and fentanyl are routinely used in medical practice primarily for 
analgesia, but also to control cough, treat diarrhea, and ameliorate “air hunger” (Banzett 
et al., 2011; Dworkin et al., 2003; Zollner and Stein, 2007). Although µ-agonists are 
unparalleled in their ability to treat pain of any modality, their therapeutic use is limited 
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by unwanted effects such as constipation, sedation, itch, physical dependence and their 
potential for abuse (Inturrisi, 2002; McNicol, 2008). 
 Pain has been referred to as the fifth vital sign, a designation that recognizes the 
salience of this symptom in human health (Lorenz et al., 2009). Adequate analgesia is 
the primary goal of pain management, and is regarded as “a moral imperative, a 
professional responsibility, and the duty of people in the healing professions” (Institute 
of Medicine, 2011). In 2010, the Patient Protection and Affordable Care Act directed the 
Institute of Medicine (IOM) to conduct research on ways to increase “the recognition of 
pain as a significant public health problem in the United States.” A subsequent report 
published by the IOM estimated that 100 million people in the United States live with 
chronic pain, and the economic costs associated with pain conditions are in excess of 
$500 billion (Institute of Medicine, 2011).  
 At the same time, opioid abuse in the United States has reached epidemic 
proportions (Han et al., 2015; Maxwell, 2011). The prevalence of prescription opioid 
abuse has reached an all time high, and the estimated number of fatalities from 
overdose is almost 45 per day (Davis et al., 2013; Han et al., 2015). This has coincided 
with the resurgence in heroin abuse, which in part, has been attributed to the perception 
among opioid abusers that heroin is a cheaper alternative to prescription opioids (Jones 
et al., 2015). Taken together, the challenges faced by the medical community are clear: 
the abuse, misuse, and diversion of prescription opioid drugs is a serious public health 
problem that must be controlled in a manner that is sensitive to the legitimate and 
essential use of these medicines.  
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 In recognition of the vital role that opioid medicines have in patient care, and the 
seriousness of the opioid epidemic, this thesis evaluates two potential strategies to 
improve the therapeutic use of opioids, with a particular emphasis on pain control. The 
first strategy explores the discriminative stimulus and analgesic effects of the 
nociceptin/orphanin FQ receptor (NOP) agonist, Ro 64-6198, in rhesus monkeys. As a 
target, the nociceptin (NOP) receptor has demonstrated several therapeutic advantages 
over the µ-opioid receptor in non-human primates (NHPs). The second strategy 
develops an experimental framework to investigate how the intranasal (IN) route of drug 
administration may be employed to improve the therapeutic use of opioid agonists and 
antagonists. A comparison of the general pharmacodynamic properties of IN and other 
parenteral routes of administration is described.    
 
A brief history of opioid receptor pharmacology 
 The actions of opioid drugs are mediated through the binding of opioid receptors, 
and the constellation of effects that are produced vary depending on the selectivity of 
the drug or ligand for one or more of these receptors (Martin, 1983). In the mid-1960s, 
Martin and colleagues postulated, and provided some of the earliest evidence, that 
different opioid agonists had distinct pharmacological properties mediated through more 
than one receptor (Martin et al., 1965; Martin and Gorodetzky, 1965; McClane and 
Martin, 1967). The approach to establishing the existence of such receptors was two 
pronged, and rooted in the foundational principles of pharmacology. First, the effects 
produced by different opioid drugs of varying efficacy were thoroughly characterized 
across different functional preparations (in vivo and in vitro), followed by an evaluation 
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of the saturable and stereospecific binding of these drugs in different tissue fractions 
(Martin, 1983). Influential work in the field by Chang and Gaddum demonstrated that 
agonists acting at one or more receptor populations could be identified by comparing 
their rank order of potency across multiple assay systems (Chang and Gaddum, 1933). 
It was later shown that different receptor populations could be more accurately 
differentiated with selective antagonists according to the methods of Arunlakshana and 
Schild. This held that the potency of a given selective antagonist to shift the agonist 
dose-effect curve two log units to the right would be identical for agonists acting at the 
same receptor (Arunlakshana and Schild, 1959; Schild, 1947). Finally, it had been 
established that opioids bound to brain homogenates in a stereoselective and saturable 
manner (Simon et al., 1973). The application of these principles across multiple systems 
would eventually lead to the discovery of three distinct opioid receptors, µ, κ, and δ. 
 In vivo evaluation supported the findings of distinct opioid systems; it was 
discovered that opioids could be broadly classified based on their relative efficacy to 
produce specific behavioral effects. Two general types of behavior were most 
commonly described, one corresponding to the effects of acute drug administration, and 
the other, the syndrome that was produced following discontinuation of the drug after a 
period of chronic administration (the “drug abstinence syndrome”) (Martin, 1979). In 
humans, following acute administration, it was noted that morphine-like drugs produced 
signs and symptoms such as itchy skin, euphoria, and talkativeness, while cyclazocine-
like analgesic compounds were associated with somnolence, drunkenness, and at 
higher doses, dysphoria (Jasinski et al., 1968; Martin and Gorodetzky, 1965; McClane 
and Martin, 1976). Parallel work performed in animals (monkeys, chronic spinal dog) 
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also supported the division of opioid drugs into at least two classes based on acute 
effects and drug abstinence (Gilbert and Martin, 1976). In the case of drug abstinence, 
agonists within the same drug class would substitute, or suppress the abstinence 
syndrome, to an extent that was reflective of their efficacy. For example, in cyclazocine-
dependent animals, morphine substitution did not suppress the abstinence syndrome 
produced following the discontinuation of cyclazocine, but these effects were completely 
reversed with ketazocine, while only partially suppressed with nalorphine (Gilbert and 
Martin, 1976). Drugs with no efficacy, such as naloxone, would precipitate the 
abstinence syndrome in subjects made physiologically dependent on either cyclazocine 
or morphine (Jasinski et al., 1967; Jasinski et al., 1968).   
 More evidence that opioids acted at a heterogeneous population of receptors 
was generated with in vitro experiments measuring smooth muscle contractions in the 
mouse vas deferens and/or guinea pig ileum (Hutchinson et al., 1975; Kosterlitz and 
Robinson, 1958; Lord et al., 1977). In 1977, Lord et al. published an elegant series of 
experiments combining the previously discussed pharmacological principles across 
several assays, which established definitively the existence of more than one opioid 
receptor type. Consistent with these findings, the relative potency of different opioid 
agonists was found to be assay-dependent, and therefore likely mediated through a 
heterogeneous population of receptors. It was determined that µ-receptors (and to a 
lesser extent κ-receptors) predominated in the guinea pig ileum, while δ receptors (and 
to a lesser extent, µ-receptors) predominated in mouse vas deferens. Moreover the 
potency of naloxone to antagonize the effects of agonists in different preparations 
varied (e.g. the potency of naloxone to antagonize the effects of the endogenous opioid 
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peptide leu-enkephalin was almost 9x greater in the guinea pig ileum than the mouse 
vas deferens). Importantly, the results from these experiments in vitro were strongly 
correlated with in vivo preparations assaying analgesia, the suppression of drug 
abstinence syndrome, and the like. For example, the rank order potency of µ-opioid 
agonists to inhibit smooth muscle contraction in the guinea pig ileum  (etorphine> 
fentanyl> levorphanol> heroin>normorphine>codeine) was retained in preparations 
measuring human analgesia and in preclinical preparations using dogs and monkeys 
(Lord et al., 1977). Thus, the pharmacology of an opioid ligand could be reliably 
confirmed across multiple assay systems.  
 More than 30 years later, the existence of three opioid receptor types µ, κ, and δ 
was further verified through molecular cloning (Waldhoer et al., 2004). Following that, a 
fourth member of the opioid family was identified entirely through amino acid sequence 
homology, and was eventually named the nociceptin/orphanin FQ peptide receptor 
(NOPr) (Mollereau et al., 1994). Although the receptor shared 60-80% sequence 
homology with the classic opioid receptors, NOPr had negligible affinity for the 
endogenous opioid peptides, and agonist stimulation of this receptor was not blocked by 
naloxone (Mogil and Pasternak, 2001). One year after its identification, the endogenous 
ligand for NOP was discovered and named nociceptin/orphanin FQ (Meunier et al., 
1995). This peptide did not bind the canonical opioid receptors, but it shared high 
sequence homology with the kappa selective peptide dynorphin A. Although classified 
as an opioid receptor, considerable differences exist between µ, κ, or δ, and NOPr.  
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The Holy Grail and less Holy alternatives 
 The quest to discover new analgesics that are as powerful as morphine without 
the unwanted effects has been dubbed the Holy Grail of opioid research (Corbett et al., 
2006). In part, the establishment of three distinct opioid receptors led to speculation that 
this may be possible, and helped to encourage a massive drug discovery effort between 
industry, government, and academia (Campbell and Lovell, 2012). The problems 
associated with opioid agonist therapies are evidenced by research estimating that 50% 
of patients report side effects that limit their effectiveness, and between 10-30% of 
patients discontinue their medication despite an established need for pain control 
(Labianca et al., 2012; McNicol, 2008). One meta-analysis concluded that the most 
common side effects of opioid analgesics were constipation, sedation, nausea, vertigo, 
vomiting, and itch (Furlan et al., 2006). While opioid abuse and dependence are not 
considered “common” side effects per se, the risk of iatrogenic drug addiction remains a 
concern among practitioners (Inturrisi, 2002; Kouyanou et al., 1997). The efforts to 
improve upon µ-agonist therapy is complicated by the knowledge that most of the 
unwanted effects are on-target (i.e. mediated through the µ-opioid receptor), meaning 
that the therapeutic and unwanted effects are difficult to disassociate. 
 The efforts undertaken to improve the medical use of opioids at the µ-receptor, 
has been an equally important goal of opioid pharmacology. In general, these 
innovations have been quite successful in their own right, and may be considered in two 
categories. The first is the development of µ-opioid receptor ligands with 
pharmacodynamic and pharmacokinetic profiles that make them well suited for a 
specific medial purpose. Among these buprenorphine, remifentanil, loperamide, 
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naloxone and naltrexone are notable. Buprenorphine is a µ-opioid receptor partial 
agonist that has become a mainstay in the treatment of opioid abuse and dependence 
(Comer et al., 2005). Among buprenorphine’s numerous positive pharmacological 
attributes, it has an unparalleled safety margin compared to other µ-agonists, and when 
used in the treatment of opioid abuse can help prevent relapse and overdose (Li et al., 
2014; Walker et al., 1995). Remifentanil is a short acting anesthetic routinely used in 
surgery (Scott and Perry, 2005). It is a full µ-agonist that is rapidly degraded by 
esterases in the blood following administration, and thus its therapeutic effects can be 
initiated and terminated with unprecedented alacrity (Stroumpos et al., 2010). 
Naltrexone is a µ-opioid antagonist that is used to treat opioid and alcohol dependence 
(Comer et al., 2006). Recently, methylated derivatives of naltrexone have been FDA 
approved to treat opioid induced constipation (Camilleri, 2011). Naloxone, another µ-
opioid antagonist, is used routinely to reverse opioid toxicity (Kim and Nelson, 2015). 
Finally, loperamide, an over-the-counter medication used to treat diarrhea is also a µ-
opioid agonist (the slowing of gastrointestinal transit was one of the earliest recognized 
medical benefits of opium derivatives). Loperamide remains unscheduled, and is not 
considered to have an abuse liability because it has poor solubility when administered 
systemically, and low absorption through the GI tract (Baker, 2007).  
 The second set of innovations generally concern formulation strategies and 
routes of administration, which complement a particular opioid drug for a specific 
indication. Long-acting formulations reduce the need for repeat drug administration, and 
provide lasting pain relief (Argoff and Silvershein, 2009). Abuse deterrent formulations 
prevent the extraction of active principles for use in an illicit manner (Vosburg et al., 
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2012; Vosburg et al., 2013). The spinal administration of opioids (either intrathecal or 
epidural), is preferred over systemic administration in some clinical situations. Implanted 
intrathecal pumps with µ-agonists (typically morphine) are given to patients with chronic 
intractable pain and/or end of life pain, and provide rapid and robust relief from suffering 
(Grass, 1992). Epidural or intrathecal administration of morphine is also the preferred 
opioid intervention for obstetric pain during childbirth (Gogarten, 2003). While this has 
not solved the problem of unwanted effects, these examples illustrate how innovations 
in the medicinal chemistry, formulation and/or route of administration can change the 
properties of opioid drugs that result in positive therapeutic benefits. 
 Drugs that bind other opioid targets, such as agonists at δ and κ-receptors, have 
also been shown to produce analgesia in humans and animals (of the two, κ-receptor 
agonists are generally considered to have greater analgesic efficacy) (Negus et al., 
1998; Walker and Young, 1993). However, selective ligands for these receptors 
produce unwanted effects that are equally or more medically complicated than µ-agonist 
(κ-agonists have been shown to produce dysphoria, and δ-agonists are convulsive) 
(Comer et al., 1993; Kumor et al., 1986). The strategy of designing non-selective opioid 
agonists (ligands that bind to more than one opioid receptor) has yielded mixed results. 
At least one such compound, butorphanol (a µ/κ-agonist), has been FDA approved for 
use in man. Although the discovery of a “Holy Grail” remains the hope, it has not 
produced a compound (opioid or non-opioid) that has supplanted the clinical use of µ-
opioid agonists.  
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Once more into the breach in the quest for the Holy Grail:  
NOPr agonists 
 The development of NOPr agonists as novel analgesic agents had an 
inauspicious beginning. When the endogenous NOP peptide was first identified and 
given to rodents, it was found to induce nociception (unlike its canonical opioid 
counterparts) and was given the name “nociceptin” (Meunier et al., 1995). Nevertheless, 
interest in this target as a novel opioid analgesic continued. The initial series 
experiments conducted in rodents with peptidic and small molecule NOPr agonists 
revealed complex effects on pain that varied as a function of route of administration and 
the pain modality (e.g., Mogil and Pasternak, 2001; Schroder et al., 2014). It was 
subsequently determined that NOPr agonists were not pronociceptive in rodents, but 
the broadest spectrum of analgesic efficacy was found only following intrathecal 
administration. While systemic administration of NOPr agonists was generally shown 
not to be effective against acute thermal nociceptive stimuli, positive results with this 
route have been achieved in neuropathic and inflammatory pain models (Khroyan et al., 
2011). Interestingly, systemic administration, or supraspinal activation of NOPr 
receptors was found to produce a functional antagonism of µ-agonist effects (Khroyan 
et al., 2009a; Khroyan et al., 2009b). These findings have led to commercial interest in 
developing mixed acting µ/NOPr agonists for pain control, at least one of which 
cebranopadol, is in Phase III (Linz et al., 2014).  
 Based on the results in rodents, it was surprising to learn that the effects of NOPr 
agonists in rhesus monkeys were considerably more straightforward. Studies in non-
human primates demonstrated that the small molecule NOPr agonists Ro 64-6198 and 
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SCH 221510 given systemically produced strong analgesia (comparable with full 
agonists at µ-receptors, such as alfentanil) (Cremeans et al., 2012; Kangas and 
Bergman, 2014; Ko and Naughton, 2009). Identical results were obtained after 
intrathecal administration of nociceptin and other peptidic agonists (Ko and Naughton, 
2009; Ko et al., 2006) Moreover, these effects were found in assays of acute thermal 
nociception as well as capsaicin-induced allodynia. Finally, these drugs did not produce 
reinforcing effects, nor did they cause pruritus or respiratory depression (Ko et al., 
2009). These results supported the continuing interest in the therapeutic profile of NOPr 
agonists, and their potential advantages over µ-agonists. However, other than 
analgesia, the behavioral effects of NOPr agonists in rhesus monkeys have remained 
uncharacterized (most of the studies have noted their relative lack of effects on a target 
behavior).  
 Drug discrimination studies have been used extensively to characterize the 
interoceptive effects of psychoactive drugs (e.g., Colpaert, 1999). Previous work in the 
laboratory demonstrated that the discriminative stimulus effects of µ, κ, and δ agonists 
are behaviorally and pharmacologically selective (Woods et al., 1988). In addition to 
providing information about the similarities and differences in the central effects of 
psychoactive drugs, drug discrimination techniques can also measure the potency of 
drugs to alter rates of responding. This provides an opportunity to measure the 
behavioral disrupting effects produced by drug administration. Through the use of 
selective antagonists, the pharmacological specificity of the discriminative stimulus and 
behavioral disrupting effects may be established (Woods et al., 1988).  
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 In contrast to µ and κ agonists, previous studies had suggested that the 
analgesic effects of NOPr agonists were observed with doses that did not produce 
sedation or behavioral disruption. Based on these findings, it was plausible that NOPr 
agonists would produce discriminative stimulus effects with doses that were smaller 
than those required to produce analgesia. If true, this would be a significant departure 
from the commonly observed order of potency for most opioids to produce these 
behavioral effects (i.e. discriminative stimulus effects > rate suppression > analgesia), 
and demonstrate one way in which NOPr agonists may have a superior therapeutic 
profile to MOP agonists. The primary purpose of the first set of experiments in this 
thesis was to characterize the discriminative stimulus effects of NOPr agonists in non-
human primates and to compare the order of potency of NOPr agonists to produce 
stimulus, rate suppressing, and analgesic effects with that of the µ-receptor agonist, 
fentanyl.  
 
 
 
And another less Holy alternative:  
Intranasal opioid administration 
 Even though the unwanted effects from µ-agonists are salient, the medically 
indispensible nature of opioids requires innovation in formulation and administration. 
Furthermore, the application of a particular opioid therapy should be aligned with the 
therapeutic goals, and used in consideration of the risks, benefits and alternatives. For 
example, in the context of pain control, the onset and duration of action, as well as the 
magnitude of effect should be congruent with the frequency, intensity, and duration of 
the pain modality (Inturrisi, 2002). The general recognition of these principles follows the 
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use of many different opioid agonists, which are employed in a variety of formulations 
and through several routes of administration (fentanyl patches, intrathecal morphine 
pumps, oral loperamide, IV remifentanil).   
 Although the bioavailability of some opioids following IN administration has been 
documented, other than butorphanol, the practice of administering opioids intranasally 
has only recently become more common following the approval of IN fentanyl for break-
through cancer pain (Grassin-Delyle et al., 2012; Prommer and Thompson, 2011). In 
general, the nose is an attractive site for drug delivery due to the relatively large surface 
area for absorption, and the ability to avoid hepatic and GI first-pass metabolism. From 
a clinical perspective, this route of administration provides a non-invasive method of 
parenteral systemic drug delivery, and produces a prompt onset of action that is 
comparable to IV injection (Foster et al., 2008; Gourlay and Benowitz, 1997). There 
have been reports of direct absorption to the CNS following IN administration, and while 
there is considerable interest in exploring this possibility, evidence for this pattern of 
absorption in primates is limited (Dhuria et al., 2010; Scheibe et al., 2008)  
 The physiochemical properties of ligands that make them suitable for IN 
absorption are not radically different than those for other parenteral routes of 
administration (good solubility, low molecular weight, high lipophilicity, if targeting CNS) 
(Arora et al., 2002). However, there are some notable differences that have important 
implications for drug development and therapeutics (for review, see Arora et al., 2002). 
The size of the intranasal cavity limits the volume that can be delivered into the nose 
without jeopardizing the reliability of dosing, and this amount varies from species to 
species. Normal mechanisms of mucosal clearance and drainage may limit drug contact 
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with anatomical regions critical for absorption. Lastly, there are enzymes present in the 
nose, including cytochrome P450s and P-glycoproteins, which may break down 
peptides and small molecules or prevent their absorption (Wioland et al., 2000; Zhang 
et al., 2005). There is a considerable body of research on formulations deigned to 
enhance IN absorption that may circumvent some of these issues, but they are beyond 
the scope of the work presented here.  
 The therapeutic potential for IN opioid administration is best illustrated with IN 
fentanyl and naloxone (NLX). The treatment of episodic breakthrough cancer pain, 
which is unpredictable and highly distressing periods of intense suffering, has been 
improved with the use of IN fentanyl (Kongsgaard et al., 2014). The ability of patients to 
control drug administration, and the prompt onset of relief that typically occurs only in 
the clinic with medication delivered by injection, has improved treatment satisfaction 
(Karlsen et al., 2013). IN NLX has gained acceptance as an alternative to intramuscular 
or intravenous administration in the treatment of opioid overdose. Again, the prompt 
onset of action, and the elimination of needles has made this appealing for use in 
emergency medicine, particularly when treating intravenous drug users who have a high 
incidence of blood borne diseases and poor intravenous access.   
   The majority of preclinical research conducted on IN drug administration, with 
the notable exception of studies investigating the effects of oxytocin, has been 
performed in rodents. Across all species, studies of IN drug administration typically 
focus on pharmacokinetics (PK), and attempts to extrapolate conclusions about 
pharmacodynamics based on these data may produce misleading conclusions. For 
example, in one published PK study in humans, it was reported that the bioavailability of 
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NLX following IN administration was only 4% relative to IV injection. As a result, the 
authors concluded that NLX would be least effective when administered by this route 
(Dowling et al., 2008). Like many PK studies of this kind, the authors relied on venous 
sampling to measure the concentration of naloxone in the blood. However, studies with 
IN nicotine and fentanyl show that, unlike when drugs are administered IV or IM, venous 
sampling may significantly underestimate the bioavailability of drug at the target, and is 
a poor predictor of pharmacodynamics (Gourlay and Benowitz, 1997; Guthrie et al., 
1999; Moksnes et al., 2008). Subsequent evidence from studies comparing IV and IN 
NLX in the context of drug overdose, have suggested the therapeutic effect are actually 
quite similar (Kerr et al., 2009). The application of other methods that could more 
directly determine the extent of ligand-target engagement, such as receptor occupancy 
studies with PET, have not been used to address the suitability of IN administration to 
produce desired therapeutic effects.  
 The purpose of the last series of experiments in this thesis was to develop and 
validate a procedure to measure the behavioral effects of IN opioid delivery in rhesus 
monkeys with the hope of establishing its translational relevance in preclinical drug 
development. There is good evidence to suggest that NHP models of IN drug effects 
may be of greater translational value relative to experiments performed in rodents. Rats 
and mice have larger nasal cavities relative to their body size, and a larger nasal 
surface area overall for drug absorption (Gross et al., 1982). Moreover, the cellular 
composition of the rodent nasal cavity is split equally between olfactory epithelium, 
which are key mediators in direct nose-to-brain absorption, and other cell types (Dhuria 
et al., 2010; Harkema et al., 2006; Hoekman and Ho, 2011). Olfactory epithelium 
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composes only 3% of nasal cavity volume in humans and 7% in monkeys. Thus, the 
different patterns of drug deposition, absorption, and distribution, between rodents and 
primates, following IN drug administration may limit the reliability of rodent models to 
predict clinical relevant pharmacodynamic end-points.    
 The lack of such translational reliability has been noted as a limiting factor in at 
least one industry perspective published by Pfizer evaluating the potential of direct 
nose-to-brain absorption (although the same principles are applicable to any goal with 
intranasal delivery) (Landis et al., 2012). Perhaps, this is the reason many therapeutics 
that are administered IN are reformulated medicines that have already gained FDA 
approval through another route. This strategy, while commercially viable, ignores the 
advantage that IN delivery offers at the early stages of drug development. Thus, ligands 
with therapeutic potential that do not have “good drug properties” associated with oral 
administration may be unnecessarily abandoned.   
 The first set of studies established the procedure for measuring the analgesic 
effects of intranasally administered opioids using fentanyl, buprenorphine, and the 
opioid peptide, MMP 2200. Basic pharmacodynamic comparisons between IN and IM 
administration were characterized for fentanyl and buprenorphine in studies of acute 
thermal nociception. The generalizability of this procedure was then assessed in 
another pain modality, capsaicin-induced allodynia, where the ability of MMP 2200 to 
reverse allodynia after IN administration was evaluated. Previous studies conducted in 
rhesus monkeys showed that IM MMP 2200 reversed capsaicin-induced allodynia 
through a peripheral mechanism of action (Do Carmo et al., 2008). It was used in these 
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experiments to establish proof-of-concept that the analgesic effects of peptides could be 
detected following IN delivery in this preparation. 
 Finally, the IN administration of opioids was extended to include naloxone, the µ-
receptor antagonist. The importance of opioid antagonists in therapeutics has been 
reaffirmed as the rates of opioid abuse and overdose reach epidemic proportions in the 
United States (Dart et al., 2015; Wermeling, 2013). While field medical studies have 
provided evidence that IN NLX can reverse opioid toxicity, its effectiveness compared to 
other more commonly used parenteral routes of administration remain unclear (Kerr et 
al., 2008; Kerr et al., 2009; Zuckerman et al., 2014). For example, the potency of IN 
NLX to block µ-agonist effects, or the reliability of IN dosing in terms of receptor 
engagement, have never been systemically evaluated. The procedures for evaluating IN 
opioids that were developed in this thesis provided a chance to investigate some of 
these issues, and illustrate how this model may be used to answer scientific questions 
that are relevant to public health. The last set of studies evaluated the potency of IN and 
IV NLX to block the antinociceptive effects of fentanyl. Since the same magnitude of 
behavioral effect may be produced with different levels of receptor occupancy, the 
degree of receptor availability following equipotent doses of NLX given IV and IN was 
measured using positron emission tomography (PET). This provided the first direct 
comparison of receptor occupancy across routes of administration. 
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Specific Aims 
Specific Aim 1. NOPr agonists have been reported to produce antinociceptive effects in 
rhesus monkeys with comparable efficacy to µ-opioid receptor agonists, but without 
their limiting side effects. There are also known to be species differences between 
rodents and NHPs in the behavioral effects of NOPr agonists. The aims of this study 
were to: 1) determine if the NOPr Ro 64-6198 could be trained as a discriminative 
stimulus, 2) evaluate its pharmacological selectivity as a discriminative stimulus, and 3) 
establish the order of potency with which Ro 64-6198 produces discriminative stimulus 
effects compared with analgesic effects in NHP.  
 
Specific Aim 2. The anatomical and physiological features of the nose that enable rapid 
and efficient drug absorption to the systemic circulation, and possibly to the CNS, make 
developing drugs for IN administration appealing. This study sought to establish the first 
procedure to measure the analgesic effects of IN opioids in rhesus monkeys. The initial 
experiments compared the ability of fentanyl and buprenorphine to increase tail-
withdrawal latency from 50°C water across two routes of administration (IN versus IM). 
The second experiment aimed to validate these procedures using a different pain 
modality, capsaicin-induced allodynia, and to evaluate the opioid peptide MMP 2200 
following IN administration. 
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Specific Aim 3. Treatment with NLX can reverse opioid toxicity if administered promptly 
following an overdose. The efforts to expand the use of NLX have included the IN route 
of administration, however, questions exist regarding the potency and effectiveness of 
IN NLX relative to more common parenteral routes of administration, such as 
intravenous injection (IV). The purpose of this study was to compare the potency of IN 
and IV NLX to block the antinociceptive effects of the µ-opioid agonist fentanyl, and to 
measure the receptor occupancy produced with equipotent doses of NLX across routes 
of administration using PET imaging. 
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CHAPTER TWO 
Characterization of the Discriminative Stimulus  
Effects of a NOP Receptor Agonist  
Ro 64-6198 in Rhesus Monkeys1 
 
 
Introduction 
 The nociceptin/orphanin FQ receptor (NOP) is a seven-transmembrane domain 
receptor that was first cloned in 1994, and was noted to share significant sequence and 
structural homology with the classic opioid receptors µ, κ, and δ (Mollereau et al., 1994). 
Despite these similarities, the canonical endogenous opioid peptides have negligible 
affinity for NOPr, as does the opioid antagonist naloxone. One year later, two separate 
groups identified a 17-amino acid peptide that bound with high affinity to NOPr as the 
endogenous ligand (Meunier et al., 1995; Reinscheid et al., 1995). This peptide was 
given two names, nociceptin and orphanin FQ (N/OFQ), and was found to share 
considerable sequence homology with the κ-selective peptide dynorphin A. Functional 
experiments in vitro demonstrated that NOPr, µ, κ, and δ all coupled predominantly to !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !!!!!!!!!!!!!!!!!!!!!1!This chapter was accepted for publication in the Journal of Pharmacology and Experimental 
Therapeutics !
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the Gαi/o class of G-proteins, and produced analogous signal transduction following 
agonist stimulation (inhibition of adenylyl cyclase, and Ca2+ conductance; stimulation of 
K+ conductance).  
 Given its classification, the initial behavioral pharmacology focused on evaluating 
the role of NOP in modifying pain-related behaviors. The results from many of these 
experiments were nuanced relative to µ-agonist effects, and there were considerable 
differences noted between rodents and non-human primates (NHPs). In rodents, the 
analgesic response to NOPr agonists varied depending on the route of administration, 
and the type of pain stimulus. There is now general agreement that NOPr agonists 
produce analgesia in rodents when given intrathecally (IT) across a variety of pain 
assays. Systemic or supraspinal administration in rodents does not produce 
antinociception against an acute thermal stimulus (tail-flick, hot-plate), but may have 
positive effects in inflammatory, neuropathic, and chronic pain states (for review, see 
Lambert, 2008; Mogil and Pasternak, 2001; Schroder et al., 2014).  
 In rhesus monkeys, however, NOPr agonists given systemically or spinally were 
shown to be antinociceptive, antiallodynic, and anti-inflammatory (Kangas and 
Bergman, 2014; Ko and Naughton, 2009; Ko et al., 2009). When administered IT, 
N/OFQ produced antinociception that was less potent, but similar in magnitude, to 
morphine. However, unlike morphine, or other µ-opioid receptor agonists given i.t., 
N/OFQ did not produce respiratory depression or pruritus. The first small molecule 
agonist to be tested systemically in monkeys, Ro 64-6198, was reported to produce 
acute thermal antinociception and to be antiallodynic (Ko et al., 2009). When compared 
with alfentanil, Ro 64-6198 was equipotent in producing antinociception, but was not 
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self-administered, and did not produce respiratory depression or itch. The 
antinociceptive effects of Ro 64-6198 were selectively blocked by the NOPr antagonist 
J-113397 and not by the opioid antagonist naltrexone. Although not systematically 
evaluated, NOPr agonists were reported to produce analgesia in the absence of 
sedation, unlike agonists at µ and κ-opioid receptors (Ko and Naughton, 2009; 
Podlesnik et al., 2011). Furthermore, whereas the preclinical literature in rodents 
showed a complex relationship between the NOP system and analgesia, the data in 
monkeys appeared to be more straightforward. 
 To our knowledge, other than analgesia, there have been no other reports 
identifying behaviors that are modified by NOPr agonists in NHPs (most of the studies 
have noted their relative lack of effects on a target behavior). Drug discrimination 
procedures are widely used to study the interoceptive properties of CNS drugs, and are 
well suited for establishing the in vivo selectively of ligands from a broad array of drug 
classes. Previous research has established that agonist stimulation of µ, κ, and δ-opioid 
receptors produced discriminative stimulus effects that are pharmacologically selective 
(Colpaert, 1999; Woods et al., 1988). Previous drug discrimination studies with Ro 64-
6198 in rats showed that it possessed stimulus properties that were unlike opioid 
agonists at µ, κ, and δ-opioid receptors (Recker and Higgins, 2004). These effects were 
selectively blocked with the NOPr antagonist, J-113397, but not with the opioid 
antagonist naltrexone. This study successfully established that, in rodents, the 
discriminative stimulus effects of Ro 64-6198 were selectively mediated through NOPr, 
and were pharmacologically and behaviorally distinct from the stimulus effects produced 
through traditional opioid receptors. However, these experiments did not examine 
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whether the stimulus effects of Ro 64-6198 were distinguishable from drugs in other 
pharmacological classes. Furthermore, the apparent species differences in terms of 
other NOPr agonist effects raised the possibility that these findings may not be 
generalizable to NHP. 
 The purpose of the present experiments was to determine if rhesus monkeys 
could be trained to discriminate Ro 64-6198, and to compare the relative potencies of 
Ro 64-6198 and the µ-agonist fentanyl in measures of analgesia, discriminative stimulus 
effects, and the ability to suppress rates of responding. We also wanted to test whether 
the stimulus effects of Ro 64-6198 were similar to other opioids, and drugs from 
different classes.  
 
Methods 
Subjects 
 In the drug discrimination studies, six adult rhesus monkeys (one female, weight, 
8 kg; five males, weights, 9-12.5 kg). were individually housed in steel cages (83.3 cm 
high x 76.2 cm wide x 91.4 cm deep) on a 12hr light/12 hr dark schedule. Their diet 
consisted of Lab Fiber Plus Monkey Diet (PMI Nutrition Intl. LLC.) that was 
supplemented with fresh fruit daily.  Water and enrichment toys were continuously 
available in the home cage. All of the monkeys used in this experiment had served as 
subjects in other studies, and had prior drug histories. In the antinociception 
experiments, three separate adult male rhesus monkeys (weights, 10-11.4 kg) were 
employed and housed under the same conditions as the drug discrimination animals. 
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One female monkey that was trained to discriminate fentanyl (weight, 8kg) was also 
used in the antinociception studies. The antinociception experiments in this animal 
commenced 118 days after drug discrimination training was discontinued. All animals 
were maintained and experiments were performed, in accordance with the Institutional 
Animal Care and Use Committee, at the University of Michigan. 
Apparatus 
 Drug discrimination experiments were conducted in the home cage seven days a 
week beginning at 12p. A metal panel was mounted on either side of the cage (20 cm 
wide x 28 cm high) that housed three response levers with three stimulus lights located 
5 cm above each lever. A food dispenser was located on the same side as the operant 
levers. In an adjacent room, computers with MED-PC software controlled all of the 
experimental procedures (Med-Associates, Georgia, Vermont, USA). 
 For warm-water tail-withdrawal studies, monkeys were trained to sit in Plexiglas 
primate chairs that were 1.5 m in height. A tea kettle with hot water was maintained at 
approximately 100°C. Cold tap water and hot water were mixed together in a Thermos 
and calibrated with a total immersion thermometer in order to obtain the desired 
temperatures. Tail-withdrawal latencies were measured using a digital stopwatch.  
Drug Discrimination Procedure 
 Monkeys were trained to discriminate either fentanyl 0.01 mg/kg from vehicle 
(n=3; monkeys BC, MI, BU) or Ro 64-6198 (0.18 mg/kg, FA; 0.1 mg/kg, IE and ST) from 
vehicle in a two-lever, single component drug discrimination procedure. FA had no 
history of operant conditioning, while IE had previous experience responding for 
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intravenous (IV) drug administration and food, and ST had a history of responding for 
food. MI and BU had no previous operant training before this experiment, and BC had 
prior experience responding both for food and IV drug administration.  
 The session began with the illumination of two green stimulus lights above the 
right and left lever. Monkeys were trained to respond on a fixed-ratio (FR) 30 schedule 
for a single 300 mg food pellet (Bio Serv, Dustless Precision Pellets® Primate, Purified: 
300 mg, Banana Flavor). Drug and vehicle/sham- paired levers were randomly assigned 
to each monkey. Pre-treatment time varied by drug condition; fentanyl animals were 
given an injection 20 minutes before the beginning of the session and Ro 64-6198 
animals were injected 30 minutes prior to the session.  Following administration of the 
training drug or sham/vehicle injection, completion of a FR 30 on the condition-
appropriate lever extinguished the green stimulus lights and illuminated the center red 
stimulus light that signaled the delivery of a food pellet. Completion of a FR 30 on the 
inappropriate lever extinguished the green stimulus lights and initiated a 10s time out 
(TO) during which responses had no scheduled consequence. Any responses emitted 
on the incorrect lever reset the response requirement on the condition-appropriate key. 
The session ended when the monkey received 75 food pellets or after 60 minutes 
elapsed.  
 In order to meet criteria for drug testing, subjects were required to emit no less 
than 85% of their total responses on the condition-appropriate lever, and to complete 
the first FR in 45 responses or less. Stimulus control was deemed adequate for testing 
when monkeys met criteria for six consecutive sessions out of seven days of training. 
Test conditions were identical to training sessions except that completion of a FR 30 on 
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either key produced a food pellet. Subsequent test sessions were carried out following 
two consecutive training sessions during which the monkey met the criteria. If the 
subject failed to meet criteria during one of these sessions, testing was suspended until 
the criteria were again satisfied for two consecutive sessions.  
 Drug substitution studies were performed using selective opioid agonists and 
other drugs that are known to produce stimulus effects from different pharmacological 
classes. The µ-agonists fentanyl and buprenorphine, the κ-agonist ketocyclazocine, and 
the δ-agonist SNC 80 were used to determine if Ro 64-6198 had interoceptive effects in 
common with drugs that act at these opioid sites. Ketocyclazocine’s κ-mediated effects 
have been demonstrated in discrimination studies in rhesus monkeys (Hein et al., 
1981); SNC 80’s δ-mediated effects have likewise been shown in rhesus monkeys 
(Brandt et al., 1999). The non-opioid drugs diazepam, phencyclidine (PCP), and 
chlorpromazine were used to further test the selectivity of Ro 64-6198’s interoceptive 
effects. These drugs were tested up to doses that suppressed rates of responding or 
where the limits in drug solubility were reached. Drugs were considered to have partially 
substituted for the training stimulus if responses on the drug-appropriate lever were in 
excess of 50%, and full generalization was interpreted as greater than 85% responding 
on the drug-paired lever.  The ability of antagonists to alter the stimulus effects of 
fentanyl and Ro 64-6198 was investigated by pretreating animals with antagonists 40 
and 50 minutes, respectively, prior to the beginning of the session.  
Acute thermal antinociception 
 For measurements of antinociception, monkeys were trained to sit in a primate 
chair and their tails were periodically immersed in water heated to 38, 42, 46, or 50° C. 
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Temperatures were tested randomly at each time point with approximately 30-60s 
between each measurement. The session began with baseline measurements recorded 
at each temperature; this was followed by a series of injections (drug or saline) in thirty-
minute cycles. Two different experimenters, who were blind to the water temperature, 
tested each temperature once 20 minutes following the injection. Water heated to 50° C 
reliably produced nociception and the subject typically withdrew its tail from the water in 
2-5s. Effective opioid analgesics raise the nociceptive threshold at this temperature and 
increase the tail-withdrawal latency as compared with saline treatment.  
Data Analysis 
  Drug discrimination data are presented as a percent of drug-appropriate lever 
responding and plotted as a function of dose. If a test compound was administered to a 
monkey more than once, an average was calculated for drug-appropriate responding in 
that condition. Mean data are presented as an average of all the monkeys in the group.  
 In the warm-water tail-withdrawal study, each point represents an average of two 
sessions with a single monkey. The averages for each monkey were then converted to 
percent maximum possible effect (%MPE) using the following calculation: %MPE=[(test 
latency−control latency)/(20 s cut-off latency−control latency)]×100.   
Drugs 
 All drugs were administered intramuscularly (IM) in volumes between 0.1- 2 ml. 
Fentanyl (Sigma Aldrich, St. Louis, MO), ketocyclazocine (Sterling-Winthrop Research 
Institute, Rensselaer, NY), phencyclidine (PCP) (Warner-Lambert/Parke-Davis, Ann 
Arbor, MI), naltrexone (NIDA, NIH), and chlorpromazine (Sigma Aldrich, St. Louis, MO) 
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were all dissolved in sterile water. Ro 64-6198 (Hoffman-La Roche, Basel, Switzerland) 
was dissolved in 10% DMSO, 10% Tween 80, and 80% sterile water for a final ratio of 
1:1:8.  J-113397 (K. Rice, NIDA, NIH) was dissolved in sterile water with 1.1 eq of 1M 
HCl. Diazepam and flumazenil  (Hoffman-La Roche, Basel, Switzerland) were dissolved 
in 50% ethanol, 30% Alkamul, and 20% sterile water. SNC 80 (K. Rice, NIDA, NIH) was 
dissolved in 0.5% HCl.  
 
Results 
 Monkeys trained to discriminate Ro 64-6198 from vehicle required an average of 
75 sessions (range, 56-95) to acquire stimulus control. FA, the first monkey to be 
trained, met criteria after 95 sessions and 3 different changes in dose (0.03, 0.32, and 
0.18 mg/kg). The remaining monkeys, IE and ST were trained to discriminate 0.1 mg/kg 
of Ro 64-6198, which required 56 and 75 sessions, respectively. The three monkeys in 
the fentanyl group were all trained to discriminate 0.01 mg/kg of fentanyl from saline 
and required an average of 97 sessions (range, 91-105) to reach criteria.  All monkeys 
in the fentanyl group started training at 0.0056 mg/kg before the dose was increased.  
 In Ro 64-6198-trained animals, increasing doses of the training drug produced 
increases in responding on the drug-appropriate lever (Figure 1.1A).  On average, 
fentanyl substitution in Ro 64-6198-trained animals did not produce significant increases 
in responding on the drug-appropriate key that satisfied the a priori criteria for stimulus 
generalization (Figure 1.1B). Doses of fentanyl between 0.0056- 0.01 mg/kg produced 
slight increases (range, 15-36%) in the number of responses on the drug lever in all 
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three Ro 64-6198-trained animals, while simultaneously producing large decreases in 
the rates of responding. Peculiarly, the lowest dose of fentanyl tested, 0.001 mg/kg, 
produced full generalization in monkey IE, but elicited responding only on the vehicle-
appropriate lever in both ST and FA.  In fentanyl-trained animals, fentanyl produced 
dose-dependent increases in drug-lever responding (Figure 1.2A). Tests of stimulus 
generalization with Ro 64-6198 did not engender responding on the drug-appropriate 
lever up to doses that suppressed rates of responding (Figure 1.2B).   
 When Ro 64-6198-trained animals were pretreated with 1 mg/kg of the NOPr 
selective antagonist J-113397, responding on the drug-paired lever was completely 
abolished.  However, pretreatment with a µ-selective dose of naltrexone (0.03 mg/kg) 
did not alter responding on the Ro 64-6198-paired lever (Figure 1.3A). In fentanyl-
trained animals, responding on the drug-paired lever was blocked by pretreatment with 
0.03 mg/kg of naltrexone but was not altered by pretreatment with J-113397 (Figure 
1.3B). No significant effects were found on rates of responding in either experiment. 
  In order to further verify that Ro 64-6198 did not produce µ-mediated stimulus 
effects in vivo, fentanyl-trained animals were pretreated with a dose of J-113397 (1 
mg/kg) that completely abolished the stimulus effect of Ro 64-1698 in Ro 64-6198-
trained animals at the highest dose tested (0.32 mg/kg). The rationale for this 
experiment was to test if eliminating the stimulus effects produced through NOP would 
unmask any µ-receptor mediated stimulus effects of Ro 64-6198. Under these 
conditions, fentanyl-trained animals responded only on the vehicle-appropriate lever 
(data not shown). 
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 The in vivo pharmacological selectivity of Ro 64-6198 was further tested with the 
κ-agonist, ketocyclazocine, the δ-agonist, SNC 80, the µ-agonist, buprenorphine, the 
NMDA antagonist, phencyclidine (PCP), the non-selective dopamine antagonist, 
chlorpromazine, and the GABAA allosteric modulator, diazepam.  Up to doses that 
suppressed rates of responding, ketocyclazocine, SNC 80, PCP, and chlorpromazine 
did not produce drug-lever responding in animals trained to discriminate Ro 64-6198 
(Figure 1.4A).  Overall, buprenorphine did not produce significant increases in drug 
lever responding in Ro 64-6198-trained animals. However, IE, the monkey that 
generalized to fentanyl at the lowest dose tested, also exhibited complete stimulus 
generalization to the lowest dose of buprenorphine (0.01 mg/kg), and partial 
generalization at the middle and high doses.  
 In fentanyl-trained animals, ketocyclazocine, PCP, chlorpromazine, and 
diazepam did not produce increases in drug lever responding (Figure 1.4B). The µ-
agonist buprenorphine produced dose-dependent increases in drug lever responding, 
and fully generalized to a fentanyl cue. SNC 80 also produced dose-dependent 
increases in the drug lever responding in fentanyl-trained animals and, at the two 
highest doses tested, produced partial generalization to a fentanyl stimulus. 
 Drug substitution studies with diazepam produced dose-dependent increases in 
Ro 64-6198-lever responding that, on average, met criteria for partial generalization 
(Figure 1.5A). All three subjects partially or fully generalized to at least one dose of 
diazepam, and at every dose tested, two out of three animals made fifty percent or more 
of their responses on the drug-appropriate lever. Ro 64-6198-lever responding following 
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diazepam was unaltered by J-113397 1 mg/kg (Figure 1.5B), and the potency of the Ro 
64-6198 training dose was similarly unaffected by flumazenil 1 mg/kg (data not shown).  
 In the warm-water tail-withdrawal procedure, fentanyl produced dose-dependent 
increases in tail-withdrawal latency in all four subjects, and in the same animals, doses 
of Ro 64-6198 up to 0.32 mg/kg did not increase tail-withdrawal latency in 3 of 4 
animals. In one animal (WD), there was an increase in tail-withdrawal latency from 2.7s 
at baseline to 15.2s, or 72% of maximum percent effect, at the highest dose tested 
(0.32 mg/kg) (Figure 1.6).    
 
Discussion 
 This is the first study to demonstrate that a NOPr agonist, Ro 64-6198, can be 
trained as a discriminative stimulus in rhesus monkeys. The interoceptive effects of Ro 
64-6198 were distinct from those mediated through other opioid receptors as evidenced 
by the lack of stimulus generalization to selective opioid agonists, and the ability of 
selective NOPr antagonists to block the Ro 64-6198-induced cue. Additional drug 
substitution studies with chlorpromazine and PCP, which have both been trained as 
discriminative stimuli (Goas and Boston, 1978; Solomon et al., 1982), also failed to 
generalize, indicating that these drugs and the receptors they bind do not contribute to a 
Ro- 64-6198 stimulus. 
 While Ro 64-6198 was shown to be 100-fold more selective for NOP in vitro, it 
possesses reasonable affinity for the µ-opioid receptor (KD approximately 50 nM) where 
it functions as a full agonist (Jenck et al., 2000; Wichmann et al., 2000). Generally, 
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studies evaluating the effects of Ro 64-6198 on analgesia, anxiety, and locomotion in 
rodents, and on analgesia in monkeys, have shown these effects are not sensitive to 
the opioid antagonists naloxone and naltrexone (Higgins et al., 2001; Ko et al., 2009; 
Varty et al., 2005). The absence of stimulus generalization to a fentanyl cue in animals 
trained to discriminate Ro 64-6198, and likewise, the absence of stimulus generalization 
to a Ro 64-6198 cue in animals trained to fentanyl, supports previous findings in rat and 
monkey that Ro 64-6198 has no appreciable efficacy at the µ-opioid receptor in vivo. To 
test this further, we attempted to “unmask” the µ-agonist effects of Ro 64-6198 by 
pretreating fentanyl-trained animals with J-113397 before administering a large dose of 
Ro 64-6198. Even under conditions where NOP activity was silent and the dose of Ro 
64-6198 was high compared to doses that produce other behavioral effects, the animals 
responded only on the vehicle-appropriate lever, further confirming that Ro 64-6198 
lacks µ-agonist effects. While it is possible that even higher doses of Ro 64-6198 may 
display some u-opioid receptor like stimulus effects, the dose tested here was high 
enough to produce significant behavioral disruption. Thus, it is unlikely that Ro 64-6198 
has any behavioral effects mediated through the µ-opioid receptor.  
 Curiously, the Ro 64-6198-trained monkey IE reported that the lowest dose of 
fentanyl (0.001 mg/kg) fully generalized to the training drug and this effect decreased as 
the dose of fentanyl was increased. Consistent with this pattern of responding, IE 
completely generalized to the µ-receptor partial agonist buprenorphine at low doses, 
while larger doses only produced partial generalization. IE had an extensive i.v. drug 
history that included working for cocaine, remifentanil, and methylphenidate, as well as 
for food, under a variety of different schedules. While we cannot rule out prior 
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experimental history as a reason for this unusual pattern of stimulus generalization, it is 
not apparent what specific aspects are impacting these data. Individual differences in 
the pharmacodynamics and/or pharmacokinetics of drugs are common, and may be 
caused by genetic differences in neurobiological makeup and in how the drug is 
absorbed, distributed, and metabolized. If significant overlap between the behavioral 
effects of Ro 64-6198 and µ-agonists continue to be reported in rhesus monkeys or any 
other species, then pharmacogenetic studies looking at genetic polymorphisms in the µ 
and NOPr, as well as the enzymes known to metabolize Ro 64-6198 may help provide 
an explanation for these findings.  
 The current study found that Ro 64-6198-trained animals partially generalized to 
the benzodiazepine diazepam. Several studies in rats have reported that Ro 64-6198 
produced anxiolytic-like effects in the elevated plus-maze, fear-potentiated startle, and 
the modified Geller-Seifter conflict test (Goeldner et al., 2012; Jenck et al., 2000; Varty 
et al., 2005). These anxiolytic-like effects were similar in magnitude to those produced 
with diazepam and alprazolam, but unlike the benzodiazepines, Ro 64-6198 was 
anxiolytic-like at doses that did not disrupt motor or cognitive performance. In rhesus 
monkeys, we found that diazepam produced partial generalization to Ro 64-6198, and 
that these effects were blocked with flumazenil but not with J-113397. Additionally, the 
potency of the Ro 64-6198 training dose was unaltered by pretreatment with flumazenil. 
This suggests that Ro 64-6198 and diazepam share components of their interoceptive 
effects, but that they are not mediated through a common receptor. In vitro binding data 
support that Ro 64-6198 has no significant affinity for the GABAA channel or the 
benzodiazepine-binding site on GABAA (Wichmann et al., 2000). To the extent that the 
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interoceptive effects produced with diazepam are related to its therapeutic efficacy, 
these data may support the use of Ro 64-6198 as a novel anxiolytic.  
 Consistent with the previous literature (France et al., 1992), monkeys readily 
learned to discriminate between fentanyl and vehicle. The effects of fentanyl were 
antagonized with µ-selective doses of naltrexone but not with J-113397. Ro 64-6198, 
diazepam, chlorpromazine, ketocyclazocine, and PCP did not produce stimulus 
generalization in fentanyl-trained animals, while the µ-agonist buprenorphine produced 
full generalization. Surprisingly, the δ-selective agonist SNC 80 produced partial 
generalization to a fentanyl cue. To our knowledge this is the first time that a δ-agonist 
has partially generalized to a µ-receptor stimulus in monkeys, although rats and 
monkeys trained to discriminate SNC 80 and other δ-agonists have shown stimulus 
generalization to drugs from other pharmacological classes such as ketamine, cocaine, 
and amphetamine (Brandt et al., 1999; Suzuki et al., 1997a; Suzuki et al., 1997b). 
These results taken in the context of the previous literature suggest that the stimulus 
effects of SNC 80 maybe more complex than previously thought. In general, however, 
these findings confirm that the stimulus effects of µ-agonists are selective. 
 Overall, in contrast to the apparent species differences in the antinociceptive 
effects, there is good concordance between the stimulus effects of Ro 64-6198 in rat 
and monkey. In rats trained to discriminate Ro 64-6198 from saline, morphine 6 mg/kg 
and buprenorphine 0.1 mg/kg, produced 40 - 50% responding on the drug-appropriate 
lever, but these doses significantly suppressed rates of responding, and there was 
considerable variability among subjects (Recker and Higgins, 2004). This is consistent 
with the present study in that Ro 64-6198-trained monkeys responded on the drug-
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appropriate lever when tested with doses of fentanyl and buprenorphine that also 
suppressed rates of responding, except that neither drug met criteria for generalization. 
Likewise, in both rat and monkey, stimulus effects of Ro 64-6198 were blocked only with 
J-113397 and not naloxone or naltrexone, and drug substitution studies with selective 
opioid agonists at κ and δ-receptors did not produce stimulus generalization in these 
animals.   
 In the present study, Ro 64-6198 did not produce antinociception against an 
acute thermal nociceptive stimulus (50° C water) in 3/4 monkeys tested. One monkey 
showed increases in tail-withdrawal latency at the highest dose of Ro 64-6198 (0.32 
mg/kg), which produced 72% of the maximum possible effect. In contrast, the µ-agonist 
fentanyl produced maximum antinociception in 4/4 animals tested.  The analgesic 
potency and efficacy of fentanyl in this experiment are consistent with previously 
published studies, and the order of potency with which fentanyl was discriminated, 
suppressed rates of responding, and produced analgesia is consistent with the 
pharmacodynamic profile of this drug across the literature (i.e., potency order of 
discrimination > rate suppression> analgesia) (Dykstra et al., 1988; France et al., 1992; 
Stevenson et al., 2003).  If this same order of potency held true for NOPr agonists, 
analgesia should have been observed at doses of 0.32 mg/kg of Ro 64-6198. However, 
very limited analgesia was observed even at this large dose of Ro 64-6198.  
Interestingly, in previous studies with rhesus monkeys, a dose of 0.03 mg/kg Ro 64-
6198 was reported to produce analgesia in the same thermal nociception assay as that 
used here (e.g. Sukhtankar et al., 2014; Ko and Naughton, 2009; Ko et al., 2009).  This 
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is an order of magnitude less than would be expected to produce analgesia if the 
commonly observed order of behavioral potency held true with this NOPr agonist.  
 The reasons for the differences in the antinociceptive efficacy of Ro 64-6198 
between studies are not clear. Limits in drug solubility prevented increasing the dose of 
Ro 64-6198 above 0.32 mg/kg, but this dose was more than an order of magnitude 
greater than the reported ED50 for antinociception published in previous studies using 
analogous procedures (Cremeans et al., 2012; Ko et al., 2009). When monkeys self-
administering remifentanil were pretreated with Ro 64-6198 0.32 mg/kg IV, there was a 
comparable decrease in rates of responding and the authors reported that this dose 
produced general sedation (Podlesnik et al., 2011). Even when accounting for 
differences in potency as a function of route of administration, there appears to be little 
difference in the potency of Ro 64-6198 to produce sedation in the present study and in 
studies where Ro 64-6198 was found to be antinociceptive. These findings suggest that 
the antinociceptive effects of Ro 64-6198 may be more variable than previously 
described.  
 Since additional NOPr agonists and antagonists were not characterized in these 
procedures, the results from this study may not be broadly generalizable to the whole 
class of compounds. This is a limitation of the present investigation. Other small 
molecule NOPr agonists, such as SCH 221510, have also been shown to produce 
antinociception in rhesus monkeys using the warm-water tail-withdrawal assay 
(Cremeans et al., 2012). SCH 221510 was subsequently found to produce analgesia in 
a novel food-reinforced antinociceptive assay where squirrel monkeys were trained to 
pull a lever heated at different temperatures for various periods of time (Kangas and 
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Bergman, 2014). This procedure appeared to be quite sensitive to different analgesics 
when compared to assays that use warm water as the thermal stimulus, and not all 
drugs that were found to be antinociceptive in warm-water tail-withdrawal were 
antinociceptive in this procedure. It will be interesting to learn whether Ro 64-6198 is 
antinociceptive in this assay. The results from these studies illustrate the importance of 
testing potential therapeutics in a variety of species, with different procedures, across 
different laboratories.  
 In sum, this study establishes that Ro 64-6198 can be trained as a discriminative 
stimulus in rhesus monkeys and that these effects are selectively mediated through the 
NOPr. The stimulus properties of Ro 64-6198 are not like other opioid agonists, but may 
share similarities with diazepam. Future studies should examine the extent to which 
drugs that act at the GABAA receptor generalize to Ro 64-6198, and whether the 
stimulus effects produced with Ro 64-6198 are characteristic of all NOPr selective 
ligands. Finally, Ro 64-6198 failed to produce antinociception in the present study 
suggesting that more research is needed to assess Ro 64-6198 and other NOPr 
agonists as novel agents for pain control.  
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Figure 1.1 Discriminative stimulus effects Ro 64-6198 in Ro 64-6198-trained 
monkeys. Discriminative stimulus and response rate effects of Ro 64-6198 in Ro 64-6198-
trained animals (A) and drug substitution studies with fentanyl (B). Data from individual 
monkeys (FA, IE, ST) and their mean (+/- SEM) are plotted (n=3). FA was trained to 
discriminate Ro 64-6198 0.18 mg/kg, and IE and ST were trained to 0.1 mg/kg. Abscissae: 
Dose in milligrams per kilogram, and vehicle responding (V). Ordinates: Percent Ro 64-
6198-Lever Responding and Response Rate (responses/second). 
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Figure 1.2 Discriminative stimulus effects of Ro 64-6198 in fentanyl-trained  
Monkeys. Discriminative stimulus and response rate effects of fentanyl in fentanyl-trained 
animals (A) and drug substitution studies with Ro-64-6198 (B). Data from individual 
monkeys (BC, MT, BU) and their mean (+/- SEM) are plotted (n=3). All animals were trained 
to discriminate fentanyl 0.01 mg/kg. Abscissae: Dose in milligrams per kilogram, and 
vehicle responding (V). Ordinates: Percent Fentanyl-Lever Responding and Response 
Rate (responses/second). 
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Figure 1.3  The effects of selective antagonists in Ro 64-6198 and fentanyl-trained 
monkeys. The effect of J-113397 (1 mg/kg) and naltrexone (0.03 mg/kg) on the 
discriminative stimulus and response rate effects of the training dose in Ro 64-6198-trained 
animals (A) and fentanyl-trained animals (B). Data are presented as the mean and (+/- 
SEM) for each group of monkeys (n=3). Abscissae: Vehicle (Veh), J-113397, and 
naltrexone (NTX) in the presence of the training drug. Ordinates: Percent Ro 64-6198-
Lever Responding (A), Percent Fentanyl-Lever Responding (B), and Response Rate 
(responses/second). 
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Figure 1.4 Drug substitution studies in Ro 64-6198 and fentanyl-trained 
Monkeys. Discriminative stimulus and response rate effects of drugs that did not substitute 
for a Ro 64-6198 stimulus (A) and discriminative stimulus and response rate effects of 
drugs that did not substitute for a fentanyl stimulus (B). Data are presented as the mean of 
three animals (+/- SEM).  Abscissae: Dose in milligrams per kilogram. Ordinates: Percent 
Ro 64-6198-Lever Responding (A), Percent Fentanyl-Lever Responding (B), and 
Response Rate (responses/second). 
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Figure 1.5 Diazepam substitution studies in Ro 64-6198-trained animals. 
Discriminative stimulus and response rate effects of diazepam in Ro 64-6198-trained 
monkeys. Diazepam alone (A) and following pretreatment with J-113397 (1 mg/kg) (B). 
Data from individual monkeys and the mean (+/- SEM) are presented. Abscissae: Dose in 
milligrams per kilogram of diazepam and vehicle responding (V). Ordinates: Percent Ro 64-
6198-Lever Responding and Response Rate (responses/second). 
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Figure 1.6 Antinociception studies with Ro 64-6198 and fentanyl. Effects of fentanyl 
and Ro 64-6198 in the warm-water tail-withdrawal assay at 50°C. Data are presented from 
individual monkeys as the mean of 2 observations (+/- SEM) and were converted to 
maximum percent effect (MPE). 
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CHAPTER THREE 
A Model to Measure the Analgesic Effects of  
Intranasally Administered Opioids  
in Rhesus Monkeys 
 
 
Introduction 
 Intranasal (IN) drug administration is a non-invasive, rapid, and efficient route of 
drug delivery (Pires et al., 2009). Currently, IN administration is used for a variety of 
therapeutics including, vaccines, chemotherapies, and analgesics. The therapeutic 
possibilities for IN drug administration are far-reaching and include: the administration, 
outside a clinical setting, of biologics and peptides as therapeutics; the ability to target 
drugs directly to the brain and CNS while reducing peripheral side effects; and the 
ability to achieve therapeutic effects at lower absolute doses with the potential to reduce 
toxicity (Born et al., 2002; Campbell et al., 2012; Dhuria et al., 2010; Fortuna et al., 
2014; Miyake and Bleier, 2015).  
 Studies performed in rodents and primates have demonstrated that IN drug 
administration circumvents hepatic first pass metabolism, avoids GI decomposition, and 
provides a rapid onset of action (e.g. Fortuna et al. 2014; Dhuria et al. 2010).  
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In humans and NHP drug absorption in the nasal cavity occurs primarily in the 
respiratory zone located between the inferior and middle turbinate (Grassin-Delyle et al., 
2012). This region has the highest surface area in the primate nose and contains a 
dense vascular network composed of the sphenopalatine, facial, and ophthalmic veins, 
which drain into the jugular, and back to the superior vena cava (Gourlay and Benowitz, 
1997; Guthrie et al., 1999).  
 In general, therapeutics delivered IN are primarily absorbed into the systemic 
circulation via the respiratory zone. However, several lines of research have suggested 
that drug administration into the nasal cavity may permit direct absorption to the brain 
that circumvents the blood brain barrier (BBB) (Dhuria et al., 2010; Johnson et al., 2010; 
Miyake and Bleier, 2015). Although the exact path that drugs travel to directly access 
the brain remains an active area of investigation, studies have shown that olfactory 
receptor neurons (ORN) located in the superior turbinate are competent to enable this 
pattern of absorption (Thorne et al., 1995). It has also been proposed that trigeminal 
nerves, which innervate the respiratory epithelium, may also play a role (Johnson et al., 
2010). While this remains a promising area of research, evidence for direct drug 
absorption from the nose into the brain is limited (Scheibe et al., 2008).  
 To date, preclinical research on IN drug administration has primarily been 
conducted in rats. Although rodents have been invaluable in establishing what is known 
about intranasal drug absorption and nasal pathology, there are anatomical differences 
between rodents and primates that may be translationally important (Harkema et al., 
2006). For example, the ratio of the nasal cavity surface area to volume was found to be 
largest in rats (51.5 cm3), compared to 7.75 cm3 in rhesus monkeys and 6.4 cm3 in 
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humans (Gross et al., 1982; Smith et al., 2004). The larger ratio indicates rodents may 
have a greater potential for drug absorption compared to primates. Additionally, the 
respiratory epithelium composes 80-90% of the nasal passage in primates, while the rat 
nasal passage is equally divided between respiratory and olfactory epithelium. Since 
drug deposition into each of these regions may represent a different route of absorption 
(CNS vs. systemic), preclinical research on intranasal delivery would benefit from more 
studies conducted across species. 
 Recently, the intranasal administration of opioids (agonists and antagonists) has 
demonstrated great clinical value. Despite their well-known side effects, opioid agonists 
remain the most widely used agent to control moderate to severe pain. Relief from 
acute, unpredictable, and highly distressing pain events, such as break-through cancer 
pain, has been improved with IN formulations of fentanyl (Karlsen et al., 2013; 
Kongsgaard et al., 2014). IN naloxone, an opioid antagonist, is being used routinely to 
reverse opioid toxicity (Kerr et al., 2008; Wermeling, 2013). Furthermore, the ease of 
administration, the rapid onset of action, and the elimination of needles have paved the 
way to increase the distribution of naloxone as one means to reduce the rising number 
of fatalities from opioid overdose (Rando et al., 2015).  
 Although IN administration has been shown to have clinical benefits, there 
remains no procedure to reliably evaluate the analgesic effects of intranasally 
administered opioids in NHP even though preclinical studies in this species have 
contributed to opioid pharmacology and the development of therapeutics. The primary 
purpose of this study was to validate a procedure to measure the analgesic effects of 
intranasal opioids, and to conduct an exploratory analysis of the pharmacodynamic 
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differences between IN and IM administration. For these experiments, two small 
molecule µ-opioid receptor agonists with different efficacies, fentanyl and 
buprenorphine, were evaluated in the warm water tail-withdrawal procedure. As a 
secondary goal, we explored the possibility of extending this procedure to other pain 
modalities, such as capsaicin-induced allodynia, and evaluated the potential of this 
model to detect the activity of peptidic opioid ligands, such as MMP 2200.  
 
Methods 
Subjects 
 Adult male rhesus monkeys (n=3) served as subjects in these studies (weights, 
10.2 - 11.4 kg). Monkeys were individually housed in custom-built steel cages (83.3 cm 
high x 76.2 cm wide x 91.4 cm deep) and kept on a 12hr light/12 hr dark schedule. 
Monkeys were fed Lab Fiber Plus Monkey Diet (PMI Nutrition Intl. LLC.) that was 
supplemented with fresh fruit daily, and water and enrichment toys were continuously 
available in the home cage. The animals were maintained, and all experiments were 
performed in accordance with the University of Michigan University Committee on Use 
and Care of Animals.  
Surgery 
 Monkeys were surgically implanted with indwelling venous catheters that were 
attached to ports located under the skin for the administration of anesthetic propofol. 
For surgery, all monkeys were anesthetized with ketamine (10 mg/kg) and xylazine (2 
mg/kg). Intravenous catheters were placed in an accessible vein and passed 
subcutaneously to the animal’s back where it was attached to the port (Access 
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Technologies, Intisil™ catheter, Attachable 5 French [0.30’/0.7mm ID x 0.065’/1.7mm 
OD x 24”/60 cm], Skokie, Illinois).  
Drug administration 
 Intranasal administration was performed with a modified nasal atomizer (MAD) 
(LMA® MAD Nasal™ Intranasal Mucosal Atomization Device, Research Triangle Park, 
NC) that was attached to a 1 ml syringe. The Styrofoam stop, and the butterfly handles 
were removed from the MAD to ensure a good fit into the monkey’s nostril. Immediately 
prior to drug administration, the monkey was anesthetized with propofol (3.3 ml of 10 
mg/ml), which was administered through the IV port. Following the onset of anesthesia, 
the monkey was reclined to an angle of approximately 45° degrees, the atomizer was 
inserted into the right or left nostril (approximately 3 cm), and the plunger was 
depressed while holding the opposing nostril closed. The monkey was held in the 
reclined position for three minutes following drug administration. Fentanyl and 
buprenorphine were delivered in volumes between 0.05 ml and 0.4 ml. Buprenorphine 
was not administered at a volume of more than 0.2 ml in a single nostril due to the 
viscous nature of the vehicle. MMP 2200 was administered in volumes between 0.3-1.0 
ml—no more than 0.5 ml per nostril. Intramuscular drug administration was performed in 
the standard manner except that propofol anesthesia was administered prior to 
injection. 
Antinociception studies 
 Monkeys were trained to sit in a Plexiglas primate chair that measured 1.5 m in 
height. The bottom portion of the tail was shaved and periodically dipped into water 
heated to 38, 42, 46, or 50° C. The desired temperature was achieved by mixing hot 
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water from a kettle (maintained at approximately 100°C) with cold tap water in a 
Thermos, which was calibrated using a total immersion thermometer. Tail-withdrawal 
latency was measured using a digital stopwatch. 
 The session began with baseline determinations performed at each temperature. 
Two experimenters measured tail-withdrawal latency at every temperature. The 
experimenter who was measuring tail-withdrawal latency was blind to the temperature 
being prepared by the other. Monkeys were anesthetized with propofol as described 
above. Following drug or vehicle administration IM or IN, the monkey was gently 
stimulated (rubbing its head and chest) to encourage rapid recovery from anesthesia. A 
monkey was determined suitable for testing when it could successfully track the 
experimenter’s finger with its eyes, and when it was capable of withdrawing its leg 
following stimulation from the experimenter. Tail-withdrawal latency was measured 
subsequently at 10, 20, 40, 60, 80, 100 and 120 minutes. No more than one session 
was performed per week. 
Capsaicin-induced allodynia 
 Allodynia experiments were conducted based on methods that have been 
reported elsewhere (Ko et al., 1998). Pilot experiments were performed using two doses 
of capsaicin (0.1 mg and 0.32 mg), while measuring tail-withdrawal latency at different 
time points relative to drug administration following capsaicin (5, 10, 15, 30, 45, 60 min). 
The final parameters were chosen based on their ability to produce reliable and 
reversible allodynia across all subjects.  
 Following baseline tail-withdrawal determinations, animals were anesthetized 
with propofol, as described above, and were given a dose of drug or saline IN. Fifteen 
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minutes later, capsaicin 0.32 mg was administered subcutaneously (SC) 5-8 cm from 
the bottom of the tail, and 15 minutes following capsaicin administration, tail-withdrawal 
latencies were measured at 38, 42, and 46° C. Water heated to 42° C was chosen as 
the thermal stimulus for these experiments because it was the highest temperature that 
reliably produced the maximum tail-withdrawal latency in the absence of capsaicin, 
while still producing rapid tail removal following capsaicin administration.  
Data analysis 
 For measures of antinociception, the average tail-withdrawal latency was 
calculated for each individual monkey, and converted to percent maximum possible 
effect (%MPE) using the following calculation: %MPE=[(test latency−control latency)/(20 
s cut-off latency−control latency)]×100. If a condition was run more than once, average 
tail-withdrawal latency was calculated for that condition within subject and then 
averaged across subjects. MPE data is presented as an average of three monkeys ± 
SEM. The data were analyzed by repeated measures ANOVA, and post-hoc analyses 
were conducted using the Holm-Sidak correction for multiple comparisons.  
 Tail-withdrawal latencies for capsaicin- induced allodynia were reported in 
seconds (s) and were not converted to MPE. Due to the variability across subjects, data 
are presented from individual monkeys.  
Drugs 
 Fentanyl (Sigma Aldrich, St. Louis, MO), and MMP 2200 (generously provided by 
Dr. Robin Polt) were dissolved in sterile saline. Buprenorphine (NIDA, NIH) was 
dissolved in 40% beta-cyclodextrin. Capsaicin (Sigma Aldrich, St. Louis, MO) was 
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dissolved in 50% ethanol. Propofol (10 mg/ml) was manufactured by Sagent 
Pharmaceuticals (Schaumburg, IL). 
 
Results 
Acute thermal antinociception 
 The time to recovery from propofol anesthesia did not differ between routes of 
administration for either fentanyl or buprenorphine experiments [Fentanyl mean: [IN] 
332.5 s (± 9.39); [IM] 343.2 s (± 12.18 SEM). Buprenorphine mean: [IN] 342.5 s (± 
9.96); [IM] 358.8 s (± 18.54)]. In the time course data presented in Figures 2.1 and 2.3, 
the measurement of tail-withdrawal latency at time-point 0 corresponds to the first 
measurement taken after the subject had recovered from anesthesia. 
 Figure 2.1 illustrates the tail-withdrawal latency, over a period of 120 min, from 
water heated to 50° C following the IN (2.1A) or IM (2.1B) fentanyl administration (0.01-
0.032 mg/kg). The largest dose of IN fentanyl (0.032 mg/kg) increased tail-withdrawal 
latency to 70% MPE at time-point 0, and tail-withdrawal latency remained at 75% MPE 
or higher for 120 min (range, 70-100%). Smaller doses of IN Fentanyl (0.01 and 0.018 
mg/kg) increased tail-withdrawal latency beginning at time-point 0 to 35 and 45% MPE, 
respectively. For the remainder of the session, IN fentanyl 0.01 mg/kg produced 
changes in tail-withdrawal latency between 16-59% MPE, and IN fentanyl 0.018 mg/kg 
produced a range of tail-withdrawal latencies between and 15-62% MPE. 
 IM fentanyl administration also increased tail-withdrawal latency from 50°C water.  
IM fentanyl (0.032 mg/kg) increased tail-withdrawal latency to 61% MPE at time point 0, 
and produced a range of effects between 49-100% MPE over the course of 120 
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minutes. A dose of 0.018 mg/kg IM increased tail-withdrawal latency to 9% MPE at the 
0 time point, and produced a range of tail-withdrawal latencies between 8-47% 
thereafter. IM fentanyl (0.01 mg/kg) produced tail-withdrawal latencies similar to those 
measured following saline injection throughout the 120-minute session.  
 Figure 2.1 presents the average peak tail-withdrawal latency produced with 
fentanyl across time. There was a main effect of dose on tail-withdrawal latency, but no 
effect of route [Dose: F(3,6) = 19.82, p ≤ 0.01]. IN fentanyl produced dose-dependent 
increases in tail-withdrawal when compared to saline administration [Fentanyl dose 
(mg/kg) vs. saline: 0.01, p ≤ 0.01; 0.018, p ≤0.01; 0.032, p ≤ 0.001]. Following IM 
administration, the two largest doses of fentanyl (0.018 and 0.032 mg/kg) produced a 
significant increase in tail-withdrawal latency [Fentanyl dose (mg/kg) vs. saline: 0.018, p 
≤0.05; 0.032, p ≤ 0.001]. An analysis of dose x route indicated a significant difference 
between IN and IM fentanyl only at a dose of 0.01 mg/kg (p ≤ 0.05).  
 Figures 2.3A and 2.3B present the tail-withdrawal latency, over a period of 120 
minutes, from water heated to 50° C following IN or IM buprenorphine administration  
(0.1-1 mg/kg). Doses of IN buprenorphine (0.1 - 1 mg/kg), produced 50% MPE or more 
beginning at the 20-minute time point that continued within the range of 49-80% for 120 
minutes.  
 IM buprenorphine also produced increases in tail-withdrawal latency. Following 
IM administration, doses of 0.32 and 1 mg/kg increased tail-withdrawal latency to 47 
and 52% MPE at 20 minutes, which continued with a similar magnitude for 120 minutes. 
The smallest dose of IM buprenorphine (0.1 mg/kg) produced an increase in tail-
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withdrawal latency of 48% at 60 minutes, which continued within the range of 32-52% 
until the 120-minute time point.     
 Figure 2.4 presents the average peak tail-withdrawal latency produced with 
buprenorphine across time. There was a main effect of buprenorphine dose on tail-
withdrawal latency, but no effect of route [Dose: F(3,6) = 11.41, p ≤ 0.01]. IN and IM 
buprenorphine produced significant increases in tail-withdrawal latency at all doses (see 
figure caption), but there were no differences between dose, or between routes of 
administration.  
Allodynia 
 Pilot studies to optimize the experimental parameters (dose of capsaicin, water 
temperature, time-intervals for measuring tail-withdrawal) took one month. Each animal 
participated in 2-4 experiments during that time. Over a subsequent period between 12-
15 weeks, two subjects (ST and RD) became desensitized to the effects of capsaicin. 
This manifested in the failure of capsaicin to produce decreases in tail-withdrawal 
latency from 42°C over time (a temperature that in absence of capsaicin is non-noxious 
and produces the maximum tail-withdrawal latency). For the purposes of evaluating the 
antiallodynic effects of IN MMP 2200, data are presented only for these two subjects 
prior to the last control experiment with IN saline where the allodynic effects of capsaicin 
were verified.  
 As shown in Figure 2.5, the administration of SC capsaicin 0.32 mg into the tail 
produced a decrease in tail-withdrawal latency from water heated to 42°C in all animals 
[mean: 4.89 s (SEM ± 0.588)]. IN MMP 2200 (1 and 3.2 mg/kg) produced a complete 
reversal of capsaicin-induced allodynia in monkey ST, while 3.2 mg/kg increased the 
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average tail-withdrawal latency for monkey WD from 4.9 to 15 s. In subject RD, neither 
3.2 mg/kg nor 10 mg/kg produced a notable increase in the average tail-withdrawal 
latency. Overall, IN MMP 2200 reversed allodynia to varying degrees in 2 of 3 animals 
tested.    
 
Discussion 
 The present study was the first to successfully establish a procedure for 
evaluating the antinociceptive and antiallodynic effects of intranasally delivered opioids 
in rhesus monkeys. In the initial experiments, the pharmacodynamics of two well-
studied opioid agonists, fentanyl and buprenorphine, were compared across two routes 
of administration (IN and IM) in the warm water tail-withdrawal assay. The results from 
this study showed that fentanyl and buprenorphine produced dose-dependent increases 
in tail-withdrawal latency across both routes of administration. Overall, the potency of 
fentanyl and buprenorphine did not significantly differ between routes, although there 
was a trend for IN administration to produce increases in tail-withdrawal latency at 
doses that were either inactive, or not significantly different from saline when 
administered IM. Relative to IM administration, there was also a trend for buprenorphine 
and fentanyl to produce a faster onset of action when given IN. Lastly, the opioid 
peptide MMP 2200 was found to reverse allodynia in 2 out of 3 monkeys following IN 
delivery. The ability to study this compound more thoroughly was limited by the finding 
that 2 out of 3 monkeys became desensitized to the effects of capsaicin.  
 In measures of acute thermal nociception, the largest dose of fentanyl (0.032 
mg/kg) given IN and IM produced a comparable onset of action, with a similar 
 66 
magnitude and duration of effect. At smaller doses of fentanyl (0.01 and 0.018 mg/kg), 
IN administration produced sizable increases in tail-withdrawal latency while the same 
doses administered IM were not significantly different from those following saline. This 
difference was most clearly illustrated with IN fentanyl (0.01 mg/kg), which produced a 
mean increase in tail-withdrawal latency across the entire session of 40% MPE, while 
IM administration of the same dose produced an 11% change. In general, fentanyl, 
which has been studied extensively in this procedure given IM/SC, does not produce 
significant increases in tail-withdrawal latency at this low dose. The overall potency for 
fentanyl to produce antinociception was similar to previously published studies (Banks 
et al., 2010; Ko et al., 1998; Stevenson et al., 2003).  
 Since IN and IM fentanyl (0.018 mg/kg) showed a very different time course, the 
data were reanalyzed to look at the effect of route averaged across time. In contrast to 
peak effects, when MPE was averaged across the session, IM fentanyl (0.018 mg/kg) 
did not produce significant increases in tail-withdrawal latency compared to saline 
whereas IN fentanyl (0.018 mg/kg) produced effects that were significantly greater than 
those produced with saline. These data demonstrated that IM fentanyl 0.018 mg/kg was 
capable of producing the same amplitude of effect, but that IN administration was 
associated with greater increases in tail-withdrawal latency per unit of time. The same 
analysis performed with fentanyl (0.01 and 0.032 mg/kg) corroborated the lack of effect 
found with IM fentanyl 0.01 mg/kg (relative to IN administration), and the comparable 
effects on tail-withdrawal produced with IN and IM fentanyl at 0.032 mg/kg. 
 The ability of IN and IM buprenorphine to produce antinociception was assessed 
in the same procedure. Doses of buprenorphine (0.1- 1 mg/kg) administered IN and IM 
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produced increases in tail-withdrawal latency that plateaued between 66- 80% MPE. 
Across routes of administration, there were no significant differences noted among peak 
effects or when averaged across time (data not shown). This “flattening” of the dose 
effect curve was consistent with buprenorphine’s partial agonist action, and a similar 
dose response function can be seen for other effects such as respiratory depression 
(Cowan et al., 1977a; Cowan et al., 1977b; Kishioka et al., 2000; Walker et al., 1995). 
This was in sharp contrast to fentanyl, which over a smaller range of doses (0.01-0.032 
mg/kg) was able to produce the maximum effect in this procedure, and the peak effects 
measured at the highest dose of fentanyl (0.032 mg/kg) reached 100% MPE in all three 
monkeys. 
 There was a trend for fentanyl and buprenorphine to have a faster onset of action 
when given IN. For fentanyl, this was most apparent when comparing the time course of 
tail-withdrawal latency produced with 0.018 mg/kg, which was active given by both 
routes of administration. The dose of IN fentanyl produced a 50% increase in tail-
withdrawal latency at the 0 time point, while when given IM 0.018 mg/kg fentanyl did not 
produce an increase of this magnitude until 40 minutes. The tendency for IN 
buprenorphine to produce a faster onset of action was likewise more apparent with 
smaller doses. At the lowest dose of buprenorphine (0.1 mg/kg), IN administration 
produced a 53% increase in MPE at the 20-minute time point, while IM buprenorphine 
produced only a 22% change that did not reach 50% until the 100-minute time point. 
The rapid onset of effects that may be achieved with IN administration, and which do 
not require any form of injection, is one of the most appealing characteristics of this 
route of administration. Some clinical studies have suggested that the 
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pharmacodynamics and pharmacokinetics of IN fentanyl, as well as other drugs such as 
nicotine, are similar those produced by IV injection (Foster et al., 2008; Gourlay and 
Benowitz, 1997; Veldhorst-Janssen et al., 2010). Thus, IN administration may provide a 
spectrum of effects that are not routinely available outside of a clinical setting.  
 In general, ligands with high lipophilicity are more soluble in membranes and 
more easily traverse the BBB regardless of route of administration. This is particularly 
important when the target of therapeutic action is located within the CNS. 
Buprenorphine (Log P = 4.98) and fentanyl (Log P = 4.05) are two highly lipophilic 
agonists that readily cross the BBB, and the use of such compounds may have made 
the opportunity to find differences in the onset of action, and the potency of these drugs 
as a function of route more likely (Cheng et al., 2007). It would be interesting to learn if 
opioid agonists with relatively lower lipophilicity such as morphine (Log P = 0.76) and 
oxycodone (Log P = 0.82) (Cheng et al., 2007; Tetko et al., 2005), would produce 
similar differences given IN and IM. Future studies may want to investigate how relative 
lipophilicity, and other physiochemical properties, impacts the antinociceptive effects of 
opioid agonists administered intranasally. 
 We were also interested in adapting this procedure to measure other pain 
modalities such as allodynia. Previous studies have shown that SC injection of 
capsaicin into the tail of rhesus monkeys produced a transient allodynia that was 
sensitive to the effects of compounds that stimulate peripheral opioid receptors in the 
absence of central opioid receptor activation (Caterina et al., 1997; Do Carmo et al., 
2008; Ko et al., 1998). Thus, the effects of peptides and small molecule opioid agonists 
that do not pass through the BBB may be detected in this preparation. MMP 2200 was 
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derived from the endogenous opioid leu-enkephalin, and is a mixed-acting µ/δ-agonist 
that was shown to reverse allodynia in rhesus monkeys through a peripheral mode of 
action (Do Carmo et al., 2008). There are certain medical conditions where effective 
pain control, with opioids or other drugs, can be achieved in the absence of CNS 
effects, and there are circumstances where this may be preferred (Stein and Lang, 
2009; Vadivelu et al., 2011). Lastly, since one of the potential benefits of IN 
administration is the ability to administer molecules that are generally not suitable for 
oral administration (e.g. peptides and proteins), we wanted to test if this model could be 
used to evaluate such compounds. 
 In two out of three animals, IN MMP 2200 (1.0 and 3.2 mg/kg) produced 
complete, and near-complete reversal of capsaicin-induced allodynia, which was 
generally consistent with previously published studies (Do Carmo et al., 2008). In one 
animal, doses up to 10 mg/kg did not significantly increase tail-withdrawal latency, 
however higher doses could not be evaluated because this subject had developed 
desensitization to the allodynia produced with capsaicin. Although the present study did 
not verify that the effects of MMP 2200 were opioid-mediated, previous work in rhesus 
monkeys demonstrated these effects were blocked with µ-selective doses of naltrexone, 
the δ-opioid antagonist naltrindole, and quaternary naltrexone (Do Carmo et al., 2008). 
However, it was also determined that doses of MMP 2200 (32 and 56 mg/kg) that 
suppressed rates of responding were not blocked with opioid antagonists suggesting 
that non-opioid receptors may be partially responsible for the effects of MMP 2200 at 
higher doses. These data provide preliminary suggestive evidence that MMP 2200 was 
bioavailable, and antiallodynic following IN delivery. Future studies assessing the 
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analgesic effects of MMP 2200 should consider examining this route of administration 
more thoroughly.  
 The finding that desensitization occurred to capsaicin-induced allodynia was 
surprising. Although this has not been reported elsewhere in the NHP literature, there 
are some notable differences between the current procedure, and those used 
previously. For example, this experiment used larger dose of capsaicin than had been 
employed in the past (0.32 mg vs. 0.1 mg). It is also possible that repeated 
administration of this dose over time produced receptor desensitization. Additionally, 
there are lines of evidence suggesting drug interactions between propofol, capsaicin, 
and the receptors they stimulate (Fischer et al., 2010; Ji et al., 2013; Nishimoto et al., 
2015; Wickley et al., 2010). Like capsaicin, propofol is an agonist of TRPV1, and 
additionally, TRPA1, another transient receptor potential-receptor that is co-localized 
with TRPV1 on nociceptive afferents, including sensory neurons (Mickle et al., 2015). 
Both receptors are thought to play a role in mediating the effects of neuropathic and 
inflammatory pain. The co-activation of these receptors with selective agonists has been 
reported to produce complex effects including sensitization, as well as desensitization at 
the receptor level. These effects of cross-receptor sensitization and desensitization 
have also been extended to the actions of propofol and capsaicin, specifically. While, 
the exact basis for capsaicin desensitization in this preparation remain unclear, it would 
be interesting to learn if these results are generalizable to different chemical irritants 
and anesthetics. At the least, it suggests that a dose of capsaicin (0.32 mg) given by 
injection into the tail of rhesus monkeys may not be appropriate for repeated use in 
these experiments.  
 71 
 Intranasal drug administration has considerable potential for a variety of 
therapeutics. We have successfully demonstrated a procedure that can be reliably used 
to detect the antinociceptive effects, and to a lesser extent, the antiallodynic effects, of 
intranasal opioids. The study confirms that IN administration with these drugs has a 
prompt onset of action, and may allow therapeutic effects to be achieved with lower 
doses relative to other routes of administration. We also presented preliminary evidence 
that the opioid peptide MMP 2200 produces antiallodynia when given IN. These 
procedures are suitable to investigate novel or clinically used agents that may be used 
to improve opioid therapy.    
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Figure 2.1 Time course of intranasal and intramuscular fentanyl in the warm water 
tail-withdrawal assay. Mean (±SEM) tail-withdrawal latency from 50°C water expressed 
as maximum percent effect (MPE) and plotted as a function of dose and time for IN (A) and 
IM (B) fentanyl administration in rhesus monkeys (n=3). Symbols: (open circles) saline; 
(light gray circles) Fentanyl 0.01 mg/kg; (dark gray circles) Fentanyl 0.018 mg/kg;  (black 
circles) Fentanyl 0.032 mg/kg. Abscissae: Time in minutes (min). Ordinates: Tail-withdrawal 
latency presented as maximum percent effect (MPE). 
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Figure 2.2 Peak effects of intranasal and intramuscular fentanyl in the warm water 
tail-withdrawal assay. Averaged (± SEM) peak measurement of  tail-withdrawal latency 
taken from the time course data  for fentanyl administered IN (black bars) and IM (gray 
bars). Abscissae: Dose of fentanyl saline, 0.01, 0.018 and 0.032 mg/kg. Tail-withdrawal 
latency presented as maximum percent effect (MPE).  Significant differences between 
buprenorphine and saline are indicated by.  * p ≤ 0.05, **  p ≤ 0.01, *** p ≤ 0.001. Significant 
differences between routes of administration are indicated by # p ≤ 0.05. 
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Figure 2.3 Time course of intranasal and intramuscular buprenorphine in the warm 
water tail-withdrawal assay. Mean (±SEM) tail-withdrawal latency from 50° C water  
expressed as maximum percent effect (MPE) and plotted as a function of dose and time for 
IN (A) and IM (B) buprenorphine administration in rhesus monkeys (n=3). Symbols:  (open 
cicrles) saline; (light gray circles) buprenorphine 0.1 mg/kg; (dark gray circles) 
buprenorphine 0.32 mg/kg;  (black circles) buprenorphine 1.0 mg/kg. Abscissae: Time in 
minutes (min). Ordinates: Tail-withdrawal latency presented as maximum percent effect 
(MPE). 
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Figure 2.4 Peak effects of intranasal and intramuscular buprenorphine in the warm 
water tail-withdrawal assay. Averaged (± SEM) peak measurement of tail-withdrawal 
latency taken from the time course data for buprenorphine administered IN (black bars) and 
IM (gray bars).  Saline and buprenorphine doses 0.1, 0.32 and 1.0 mg/kg. Tail-withdrawal 
latency presented as maximum percent effect (MPE).  Significant differences between 
buprenorphine and saline are indicated by.  * p ≤ 0.05, **  p ≤ 0.01, *** p ≤ 0.001. 
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Figure 2.5 Effects of IN MMP 2200 on capsaicin-induced allodynia. Mean tail-
withdrawal latency from 42°C water before and after 0.32 mg capsaicin in individual 
monkeys administered IN saline or different doses of MMP 2200. Abscissae: Latency to 
withdrawal tail from 42°C water in seconds (s). Ordinates: Control measurements taken 
before capsaicin administration, IN saline followed an injection of 0.32 mg capsaicin into the 
tail, and different doses on IN MMP 2200. 
 
 
Control Cap 0.32 +
IN Saline
MMP 2200
1.0 mg/kg
MMP 2200
3.2 mg/kg
0
5
10
15
20
Ta
il-
w
ith
dr
aw
al
 
la
te
nc
y 
(s
)
42
°C
 W
ate
r
Control Cap 0.32 mg +
IN Saline
MMP 2200
3.2 mg/kg
MMP 2200
10 mg/kg
0
5
10
15
20
Control Cap 0.32 mg +
IN Saline
MMP 2200
 1.0 mg/kg
MMP 2200 
3.2 mg/kg
0
5
10
15
20
ST RD WD
 77 
 
REFERENCES 
 
Banks ML, Folk JE, Rice KC and Negus SS (2010) Selective enhancement of fentanyl-
induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus 
monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu 
opioid analgesics. Pharmacology, Biochemistry, and Behavior 97:205-212. 
 
Born J, Lange T, Kern W, McGregor GP, Bickel U and Fehm HL (2002) Sniffing 
neuropeptides: a transnasal approach to the human brain. Nature Neuroscience 5:514-
516. 
 
Campbell C, Morimoto BH, Nenciu D and Fox AW (2012) Drug development of 
intranasally delivered peptides. Therapeutic Delivery 3:557-568. 
 
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD and Julius D (1997) 
The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 
389:816-824. 
 
Cheng T, Zhao Y, Li X, Lin F, Xu Y, Zhang X, Li Y, Wang R and Lai L (2007) 
Computation of octanol-water partition coefficients by guiding an additive model with 
knowledge. Journal of Chemical Information and Modeling 47:2140-2148. 
 
Cowan A, Doxey JC and Harry EJ (1977a) The animal pharmacology of buprenorphine, 
an oripavine analgesic agent. British Journal of Pharmacology 60:547-554. 
 
Cowan A, Lewis JW and Macfarlane IR (1977b) Agonist and antagonist properties of 
buprenorphine, a new antinociceptive agent. British Journal of Pharmacology 60:537-
545. 
 
Dhuria SV, Hanson LR and Frey WH, 2nd (2010) Intranasal delivery to the central 
nervous system: mechanisms and experimental considerations. Journal of 
Pharmaceutical Sciences 99:1654-1673. 
 
Do Carmo GP, Polt R, Bilsky EJ, Rice KC and Negus SS (2008) Behavioral 
pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys. The 
Journal of Pharmacology and Experimental Therapeutics 326:939-948. 
 
Fischer MJ, Leffler A, Niedermirtl F, Kistner K, Eberhardt M, Reeh PW and Nau C 
(2010) The general anesthetic propofol excites nociceptors by activating TRPV1 and 
TRPA1 rather than GABAA receptors. The Journal of Biological Chemistry 285:34781-
34792. 
 
Fortuna A, Alves G, Serralheiro A, Sousa J and Falcao A (2014) Intranasal delivery of 
systemic-acting drugs: Small-molecules and biomacromolecules. European Journal of 
Pharmaceutics and Biopharmaceutics 88:8-27. 
 78 
Foster D, Upton R, Christrup L and Popper L (2008) Pharmacokinetics and 
pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after 
oral surgery. The Annals of Pharmacotherapy 42:1380-1387. 
 
Gourlay SG and Benowitz NL (1997) Arteriovenous differences in plasma concentration 
of nicotine and catecholamines and related cardiovascular effects after smoking, 
nicotine nasal spray, and intravenous nicotine. Clinical Pharmacology and Therapeutics 
62:453-463. 
 
Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le 
Guen M, Fischler M and Devillier P (2012) Intranasal drug delivery: an efficient and non-
invasive route for systemic administration: focus on opioids. Pharmacology & 
Therapeutics 134:366-379. 
 
Gross EA, Swenberg JA, Fields S and Popp JA (1982) Comparative morphometry of 
the nasal cavity in rats and mice. Journal of Anatomy 135:83-88. 
 
Guthrie SK, Zubieta JK, Ohl L, Ni L, Koeppe RA, Minoshima S and Domino EF (1999) 
Arterial/venous plasma nicotine concentrations following nicotine nasal spray. European 
Journal of Clinical Pharmacology 55:639-643. 
 
Harkema JR, Carey SA and Wagner JG (2006) The nose revisited: a brief review of the 
comparative structure, function, and toxicologic pathology of the nasal epithelium. 
Toxicologic Pathology 34:252-269. 
 
Ji W, Cui C, Zhang Z and Liang J (2013) Paradoxic effects of propofol on visceral pain 
induced by various TRPV1 agonists. Experimental and Therapeutic Medicine 5:1259-
1263. 
 
Johnson NJ, Hanson LR and Frey WH (2010) Trigeminal pathways deliver a low 
molecular weight drug from the nose to the brain and orofacial structures. Molecular 
Pharmaceutics 7:884-893. 
 
Karlsen AP, Pedersen DM, Trautner S, Dahl JB and Hansen MS (2013) Safety of 
Intranasal Fentanyl in the Out-of-Hospital Setting: A Prospective Observational Study. 
Annals of Emergency Medicine. 
 
Kerr D, Dietze P and Kelly AM (2008) Intranasal naloxone for the treatment of 
suspected heroin overdose. Addiction 103:379-386. 
 
Kishioka S, Paronis CA, Lewis JW and Woods JH (2000) Buprenorphine and 
methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus 
monkeys. European Journal of Pharmacology 391:289-297. 
 
 79 
Ko MC, Butelman ER and Woods JH (1998) The role of peripheral mu opioid receptors 
in the modulation of capsaicin-induced thermal nociception in rhesus monkeys. The 
Journal of Pharmacology and Experimental Therapeutics 286:150-156. 
 
Kongsgaard UE, Eeg M and Greisen H (2014) The use of Instanyl(R) in the treatment of 
breakthrough pain in cancer patients: a 3-month observational, prospective, cohort 
study. Supportive Care in Cancer22:1655-1662. 
 
Mickle AD, Shepherd AJ and Mohapatra DP (2015) Sensory TRP channels: the key 
transducers of nociception and pain. Progress in Molecular Biology and Translational 
Science 131:73-118. 
 
Miyake MM and Bleier BS (2015) The blood-brain barrier and nasal drug delivery to the 
central nervous system. American Journal of Rhinology & Allergy 29:124-127. 
 
Nishimoto R, Kashio M and Tominaga M (2015) Propofol-induced pain sensation 
involves multiple mechanisms in sensory neurons. European Journal of Physiology 
467:2011-2020. 
 
Pires A, Fortuna A, Alves G and Falcao A (2009) Intranasal drug delivery: how, why and 
what for? Journal of Pharmacy & Pharmaceutical Sciences 12:288-311. 
 
Rando J, Broering D, Olson JE, Marco C and Evans SB (2015) Intranasal naloxone 
administration by police first responders is associated with decreased opioid overdose 
deaths. The American Journal of Emergency Medicine 33:1201-1204. 
 
Scheibe M, Bethge C, Witt M and Hummel T (2008) Intranasal administration of drugs. 
Archives of Otolaryngology--Head & Neck Surgery 134:643-646. 
 
Smith TD, Bhatnagar KP, Tuladhar P and Burrows AM (2004) Distribution of olfactory 
epithelium in the primate nasal cavity: are microsmia and macrosmia valid 
morphological concepts? The Anatomical Record Part A, Discoveries in Molecular, 
Cellular, and Evolutionary Biology 281:1173-1181. 
 
Stein C and Lang LJ (2009) Peripheral mechanisms of opioid analgesia. Current 
Opinion in Pharmacology 9:3-8. 
 
Stevenson GW, Folk JE, Linsenmayer DC, Rice KC and Negus SS (2003) Opioid 
interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on 
schedule-controlled responding and thermal nociception. The Journal of Pharmacology 
and Experimental Therapeutics 307:1054-1064. 
 
Tetko IV, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P, Palyulin VA, 
Radchenko EV, Zefirov NS, Makarenko AS, Tanchuk VY and Prokopenko VV (2005) 
Virtual computational chemistry laboratory--design and description. Journal of 
Computer-aided Molecular Design 19:453-463. 
 80 
 
Thorne RG, Emory CR, Ala TA and Frey WH, 2nd (1995) Quantitative analysis of the 
olfactory pathway for drug delivery to the brain. Brain Research 692:278-282. 
Vadivelu N, Mitra S and Hines RL (2011) Peripheral opioid receptor agonists for 
analgesia: a comprehensive review. Journal of Opioid Management 7:55-68. 
 
Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH, Kessels AG, Theunissen HM, 
van der Hulst RR, Neef C and Marcus MA (2010) Pharmacokinetics, analgesic effect, 
and tolerability of a single preprocedural dose of intranasal fentanyl in patients 
undergoing drain removal after breast reduction or augmentation surgery: A 
prospective, randomized, double-blind, placebo-controlled study. Clinical Therapeutics 
32:1427-1436. 
 
Walker EA, Zernig G and Woods JH (1995) Buprenorphine antagonism of mu opioids in 
the rhesus monkey tail-withdrawal procedure. The Journal of Pharmacology and 
Experimental Therapeutics 273:1345-1352. 
 
Wermeling DP (2013) A response to the opioid overdose epidemic: naloxone nasal 
spray. Drug Delivery and Translational Research 3:63-74. 
 
Wickley PJ, Yuge R, Russell MS, Zhang H, Sulak MA and Damron DS (2010) Propofol 
modulates agonist-induced transient receptor potential vanilloid subtype-1 receptor 
desensitization via a protein kinase Cepsilon-dependent pathway in mouse dorsal root 
ganglion sensory neurons. Anesthesiology 113:833-844. 
 
 !
 
 
 
 
 
 
 
 
 
 81 
 
 
 
CHAPTER FOUR 
Intranasal versus Intravenous Naloxone:  
Behavioral Effects and Receptor Occupancy  
Studies Using PET Imaging 
 
 
Introduction  
 Opioid antagonists, such as naloxone (NLX) and naltrexone (NTX), are used 
therapeutically to treat opioid dependence and for the reversal of opioid-induced toxicity 
(Comer et al., 2006; Kampman and Jarvis, 2015; McAuley et al., 2015). Over the last 
several years, there has been a dramatic increase in the number of opioid overdoses in 
the United States, which cause almost 45 deaths per day (Jones, 2012; Levy et al., 
2015). The reasons for this have been attributed to many factors including, the increase 
in prescription opioid treatment, an increase in prescription opioid abuse, and a 
resurgence in heroin use (Cicero et al., 2014; Dart et al., 2015).  
 Naloxone is a competitive, neutral antagonist that binds with high affinity to the µ- 
opioid receptor, which is responsible for mediating both the therapeutic and toxic effects 
of most clinically used opioid agonists. Once only available to paramedics and other 
clinical personnel, there has been a concerted effort to widen access to NLX as a 
response to the US opioid epidemic (Fortuna et al., 2014; Wermeling, 2013). Naloxone 
“kits” are now being distributed to a broader range of first responders, including police 
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officers, as well as to opioid users themselves. Thus, the availability of NLX, particularly 
for intranasal (IN) use, is increasing (Doe-Simkins et al., 2014; Rando et al., 2015; 
Wheeler et al., 2015).  
 IN drug delivery is an emerging route of administration that is currently used for a 
variety of therapeutics including vaccines, chemotherapies, analgesics, and emergency 
rescue medications (Pires et al., 2009). It is attractive from a clinical and medications 
development perspective because it has several advantages over oral, and more 
common parenteral routes of delivery, such as the avoidance of GI decomposition and 
hepatic first-pass metabolism (Fortuna et al., 2014). In general, IN administration is an 
efficient, non-invasive, and rapid delivery method to the systemic circulation, although 
some have argued that IN drug delivery has the potential to result in direct absorption to 
the CNS that circumvents the blood brain barrier (BBB) (Dhuria et al., 2010). However, 
evidence for this type of absorption is limited (Scheibe et al., 2008). 
 Traditionally, naloxone was administered either intramuscularly (IM) or 
intravenously (IV) in a suspected case of opioid overdose. Both routes of administration 
are sufficient to reverse respiratory depression, which is the basis of opioid toxicity, and 
there are generally no adverse effects associated with its use (Boyer, 2012; Kerr et al., 
2008). For the past several years, IN administration of NLX has been evaluated as an 
effective and rapid alternative to IM and IV administration. This route has the advantage 
of reducing needle stick injuries when working with a population that is at increased risk 
for carrying infectious diseases, such as HIV and Hepatitis C (Akselrod et al., 2014; 
Broz et al., 2014; Kerr et al., 2008). In addition, many intravenous drug users (IDUs) 
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have poor intravenous access, which is a limitation to administering NLX intravenously 
(Coffin et al., 2012; Maliphant and Scott, 2005).  
 Although IN NLX is gaining acceptance, there have been no laboratory-controlled 
studies evaluating the potency of NLX to reverse opioid agonist effects as a function of 
route of administration, and some practitioners still question the effectiveness of IN NLX 
compared to IV or IM delivery (Zuckerman et al., 2014). In general, field research 
suggests that IN NLX reliably reverses opioid toxicity in humans, however inconsistent 
study designs, primary endpoints, and preparations of NLX (dose, concentration, 
volume etc.) make it difficult to assess how the pharmacodynamics of NLX change with 
different routes of administration. For example, in an unblinded, randomized trial of IM 
versus IN naloxone (2 mg) for opioid overdose in humans, it was found that IM naloxone 
restored respiration more quickly than IN naloxone (6 and 8 min, respectively), although 
both routes effectively rescued patients from overdose (Kelly et al., 2005). A follow-up 
study found that using a more concentrated form of naloxone at the same dose resulted 
in no difference in the latency of IN and IM naloxone to restore respiration (Kerr et al., 
2009). Barton et al. compared naloxone IV (1-2 mg) or IN (2 mg) for opioid overdose in 
humans, and found that both produced clinically significant recovery within 3 minutes 
(Barton et al., 2005). However, the paramedic subjectively determined the choice of 
which route to use, the initial dose of drug IV, and the presence or absence of clinically 
significant effects. Lastly, Sabzghabaee and colleagues (2014), in an unblinded, 
randomized study of IN versus IV naloxone (0.4 mg) administered in a poison control 
center for suspected opioid overdose, reported that IN naloxone produced significantly 
higher levels of consciousness. Both routes of administration were found to restore 
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respiration within 3 minutes, and the authors attributed the rapid recovery with IN 
administration to drug being directly absorbed into the CNS. These studies, while 
essential, were performed in emergency situations where rigorous experimental controls 
are difficult to establish, and the patient’s drug history, or the time elapsed since agonist 
administration, cannot be known. Thus, it is impossible to make any concrete 
pharmacological characterizations about IN naloxone based on this research alone. 
 Despite the widespread use of IN NLX, there are no laboratory-controlled (clinical 
or preclinical) studies systematically evaluating the potency of NLX to antagonize opioid 
effects as a function of route of administration. We have developed a novel procedure to 
measure the behavioral effects of opioid drugs following IN administration in rhesus 
monkeys. The goals of this study were to evaluate the potency of IN and IV NLX to 
antagonize the antinociceptive effects of the µ-agonist fentanyl. Using a parallel design, 
we also evaluated the ability of IN and IV naloxone to displace [11C]carfentanil 
([11C]CFN) using positron emission tomography (PET) imaging.  
 
Methods 
Subjects 
 Three male rhesus monkeys (weights, 10-11.4 kg) were subjects in the 
antinociception studies and two females (weights, 7.4-8.5 kg) were used in the PET 
study. All monkeys were individually housed in steel cages (83.3 cm high x 76.2 cm 
wide x 91.4 cm deep) on a 12hr light/12 hr dark schedule. Monkeys were fed Lab Fiber 
Plus Monkey Diet (PMI Nutrition Intl. LLC.) that was supplemented with fresh fruit daily. 
Water and enrichment toys were available continuously in the home cage. Each 
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monkey had served in previous studies and had an extensive drug history. All animal 
studies were conducted in accordance with the standards set by the University of 
Michigan University Committee on Use and Care of Animals. 
Surgery 
 Monkeys were surgically implanted with ports to allow for convenient IV 
administration of fentanyl and propofol. Surgeries were conducted under sterile 
conditions with the use of anesthesia (ketamine,10 mg/kg; xylazine, 2 mg/kg). IV 
catheters were implanted in an accessible vein, and then passed subcutaneously to the 
animal’s back where it was attached to a port that was maintained subcutaneously 
(Access Technologies, Intisil™ catheter, Attachable 5 French [0.30’/0.7mm ID x 
0.065’/1.7mm OD x 24”/60 cm], Skokie, Illinois).  
Drug Administration  
 Intranasal administration was performed with a modified nasal atomizer (MAD) 
(LMA® MAD Nasal™ Intranasal Mucosal Atomization Device, Research Triangle Park, 
NC) that was attached to a 1 ml syringe. The Styrofoam stop, and the butterfly handles 
were removed from the MAD to ensure a good fit into the monkey’s nostril. Prior to drug 
administration, the monkey was anesthetized with propofol (3.3 ml of 10 mg/ml), which 
was administered through the IV port, and flushed with 3 ml of sterile saline. Following 
the onset of anesthesia, the monkey was reclined to an angle of approximately 45° 
degrees, the atomizer was inserted into the right or left nostril (approximately 3 cm), and 
the plunger was depressed while holding the opposing nostril closed. The monkey was 
held in the reclined position for three minutes following drug administration. NLX was 
delivered in a volume between 0.05 and 0.2 ml. The monkey remained in the reclined 
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position for three minutes. IV NLX and fentanyl administration also occurred through the 
IV port, and were flushed through with 3 ml of sterile saline.  
Antinociception 
 Antinociception was measured using the warm-water tail-withdrawal procedure 
(Dykstra and Woods, 1986). Monkeys were trained to sit in Plexiglas primate chairs that 
measured 1.5 m in height. A tea kettle with hot water was maintained at approximately 
100°C. Cold tap water and hot water were mixed together in a Thermos and calibrated 
with a total immersion thermometer in order to obtain the desired temperatures. Tail-
withdrawal latencies were measured using a digital stopwatch. 
 The session began with baseline determinations of tail-withdrawal latency in 
water heated to 38, 42, 46, or 50° C. Two experimenters alternated in measuring tail- 
withdrawal latency and preparing the water bath; the experimenter measuring tail-
withdrawal latency was blind to the water temperature. Two determinations were made 
at each temperature. Monkeys were anesthetized with propofol prior to IN or IV NLX 
administration. Ten minutes after NLX (or saline) delivery, IV fentanyl (0.018 mg/kg) 
was administered and measurements of tail-withdrawal latency began ten minutes later. 
Subsequent measurements were recorded at 20, 30, 40, 50, 60, and 90 minutes 
following fentanyl injection.     
Primate MicroPet Imaging 
 Imaging studies were performed in two mature female rhesus monkeys. The 
animals were anesthetized in the home cage with ketamine and transported to the PET 
facility. Subjects were intubated for mechanical ventilation, and anesthesia was 
continued with isoflurane. Anesthesia was maintained throughout the duration of the 
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PET scan. A venous catheter was inserted into one hind limb and the monkey was 
placed on the PET gantry with their head secured to prevent motion artifacts. The nasal 
atomizer was placed into the nasal passage and secured with surgical tape to prevent 
movement. The atomizer was attached to extension tubing so the dose could be 
administered without interfering with the data collection. Following a transmission scan, 
IV or IN NLX (or saline) was administered. Ten minutes later, 3.5 mCI - 5.3 mCI of CFN 
was administered in a bolus dose over 1 minute.  Emission data were collected 
beginning with the injection and continued for 60 min (12x5 min frames). Data were 
corrected for attenuation and scatter, and reconstructed using the 3D maximum a priori 
method (3D MAP algorithm). 
 [11C]CFN was prepared as previously described (Shao et al., 2011). Briefly, 
[11C]methyl triflate was bubbled through a solution of desmethyl carfentanil - tetrabutyl 
ammonium salt (0.4 mg in dimethyl sulfoxide (100 µL)) at 15 mL/min for 3 min at room 
temperature. After production, 1% ammonium hydroxide (1 mL) was added to the 
reaction vessel. The crude reaction mixture was diluted with 5 mL of 1% ammonium 
hydroxide, and the resulting mixture was passed through a 3M Empore C2 extraction 
disk where the [11C]CFN was trapped. The disk was then washed with 3 mL of 10% n-
propanol followed by 7mL Milli-Q water to remove impurities. The disk was then dried 
(He gas) for 1 min, and the [11C]CFN was eluted off with ethanol (0.5 mL) and diluted 
with Sterile Water for Injection, USP (9.5 mL). The formulated product was then passed 
through a 0.22-µm filter into a sterile dose vial and analyzed for pH, radiochemical purity 
and cold mass. 
Data analysis  
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Antinociception 
 In the studies of antinociception, the mean tail-withdrawal latency was calculated 
for each individual monkey, and then averaged across subjects. These values were 
converted to percent maximum effect (%MPE) using the following calculation: 
%MPE=[(test latency−control latency)/(20 s cut-off latency−control latency)]×100. Data 
were analyzed by repeated measures analysis of variance using the Holm-Sidak 
correction for multiple comparisons.   
PET Analysis 
 The dynamic sequence of PET images were summed and volumes-of-interest 
(VOIs) were drawn manually on multiple planes for the thalamus, striatum, pons, 
temporal cortex, frontal cortex and parietal cortex of the control scan for each monkey. 
Images from all subsequent [11C]CFN scans following NLX blocking studies were 
registered to the that monkey’s baseline scan using the NeuroStat package available on 
the web, in order to allow image data to be extracted using the same set of VOIs. These 
data were used to construct brain tissue-radio activity curves that were then analyzed 
with the method of Logan using the occipital cortex as a reference region (Logan et al., 
1996). Changes in receptor occupancy were estimated from the distribution volume 
ratio (DVR) calculated from each VOI in the baseline scan compared with the DVRs 
obtained from the NLX blocking studies, using the formula:  
occupancy (%)  =  100 * [1- (DVRblock-1)/(1-DVRbase-1)]. 
Drugs 
 Fentanyl (Sigma Aldrich, St. Louis, MO), and naloxone (NIDA, NIH) was 
dissolved in sterile saline, and buprenorphine (NIDA, NIH) was dissolved in 40% beta-
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cyclodextrin. Propofol (10 mg/ml) was manufactured by Sagent Pharmaceuticals 
(Schaumburg, IL).  
 [11C]CFN was prepared as previously described (Shao et al., 2011). Briefly, 
[11C]methyl triflate was bubbled through a solution of desmethyl carfentanil - tetrabutyl 
ammonium salt (0.4 mg in dimethyl sulfoxide (100 µL)) at 15 mL/min for 3 min at room 
temperature. After production, 1% ammonium hydroxide (1 mL) was added to the 
reaction vessel. The crude reaction mixture was diluted with 5 mL of 1% ammonium 
hydroxide, and the resulting mixture was passed through a 3M Empore C2 extraction 
disk where the [11C]CFN was trapped. The disk was then washed with 3 mL of 10% n-
propanol followed by 7mL Milli-Q water to remove impurities. The disk was then dried 
(He gas) for 1 min, and the [11C]CFN was eluted off with ethanol (0.5 mL) and diluted 
with Sterile Water for Injection, USP (9.5 mL). The formulated product was then passed 
through a 0.22-µm filter into a sterile dose vial and analyzed for pH, radiochemical purity 
and cold mass. 
 
Results 
 Figure 3.1 presents the time course of effects for a fixed dose of IV fentanyl 
(0.018 mg/kg) alone, and in the presence of IN (A) and IV (B) NLX (0.0032-0.032 
mg/kg) on tail-withdrawal latency. The 0 time point on the graph corresponds with IV 
fentanyl injection, which occurred 10 minutes after IV or IN NLX. IV Fentanyl (0.018 
mg/kg) following saline administration produced peak antinociceptive effects of 97% 
MPE 10 minutes following injection, which decreased to 50% by the 50-minute time 
point, and then to 37% at the end of the 90-minute session. Since there were no 
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statistical differences between saline conditions, these data were averaged across 
routes for the purpose of analysis. 
 In the presence of IN NLX (0.032 mg/kg), the ability of fentanyl to produce 
increases in tail-withdrawal latency was greatly reduced. Whereas fentanyl alone 
increased tail-withdrawal between 80-97% MPE within the first 30 minutes, pretreatment 
with IN NLX (0.032 mg/kg) reduced this range of effects between 12-24% MPE. 
Likewise, IN NLX (0.01 mg/kg) reduced fentanyl-induced antinociceptive effects 
between 34-39% MPE within the first 30 minutes. Pretreatment with the lowest dose of 
IN NLX (0.0032 mg/kg) was less effective at altering the antinociceptive effects of 
fentanyl, producing tail-withdrawal latencies between 58-91% over the same time 
period. IV NLX (0.032 mg/kg) also blocked the antinociceptive effects of fentanyl, and 
decreased tail-withdrawal latencies between 0-3% MPE within the first 30 minutes.  
Similarly, the intermediate and smallest dose of IV NLX (0.01 and 0.0032 mg/kg) 
reduced the antinociceptive effects of IV fentanyl between 7-21% and 37-71% MPE, 
respectively.  
 Dose-response curves for IN and IV NLX were constructed by taking the average 
tail-withdrawal latency across the 90-minute session for each dose (Figure 3.2). 
Pretreatment with NLX given IV and IN produced dose-dependent antagonism of 
fentanyl-induced antinociception [Dose: F(3,6)= 19.49, p≤ 0.01]. For IN NLX, doses of 
0.01 and 0.032 mg/kg were significantly different from fentanyl alone [IN NLX dose 
(mg/kg) vs. saline: 0.01, p ≤ 0.01; 0.032, p ≤0.01].  Likewise, IV NLX produced 
significant decreases in MPE relative to the effects with fentanyl alone [IV NLX dose 
(mg/kg) vs. saline: 0.0032, p ≤ 0.05; 0.01, p ≤0.01; 0.032, p ≤ 0.001]. No significant 
 91 
differences were found between routes of administration in their ability to reverse 
fentanyl-induced antinociception.  
 Figure 3.3 presents the brain tissue time-radioactivity curves for [11C]CFN 
following IN saline, and IN and IV NLX (0.032 mg/kg) for selected brain regions. Under 
baseline conditions (IN saline) [11C]CFN showed rapid uptake into the brain that peaked 
between 5-10 minutes. Regions of high radiotracer uptake included the striatum, pons, 
and thalamus, and regions of lower uptake were found in cortical regions (anterior-
temporal cortex and frontal cortex). Pretreatment with IN or IV NLX (0.032 mg/kg) 
resulted in a more rapid clearance of [11C]CFN from the brain. The change in DVR 
relative to [11C]CFN alone following IN NLX (0.032 mg/kg) showed a 56-66% decrease 
in available RO across the sampled brain regions (Figure 3.4). Blocking of [11C]CFN 
was highest in the parietal and frontal cortex and lowest in the temporal cortex following 
IN administration. IV NLX showed 67-83% change in RO, with the highest region of 
blocking in the frontal cortex and the lowest in parietal. Numerically, there was a trend 
for IV NLX to produce a greater decrease in RO than IN naloxone. Figure 3.5 presents 
representative microPET images, summed across the scan, for [11C]CFN alone (top 
row), and following blocking studies with IN (middle row) and IV NLX (0.032 mg/kg) 
(bottom row). These images confirm the reduction in tracer uptake in the presence of 
NLX. 
Discussion 
 The primary findings of this study are as follows. IN and IV NLX both produced 
dose-dependent decreases in fentanyl-induced antinociception. In general, the route of 
administration did not significantly alter the potency of NLX to block the antinociceptive 
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effects of IV fentanyl. The largest dose of NLX (0.032 mg/kg) given IN and IV 
completely antagonized increases in tail-withdrawal latency that were produced with 
fentanyl. At the intermediate dose (0.01 mg/kg), IN and IV NLX both produced 
significant decreases in antinociception, although the effects produced with IV NLX 
were numerically greater than those produced by IN route. A dose of 0.0032 mg/kg NLX 
given IV significantly decreased fentanyl-induced antinociception relative to fentanyl 
alone, while the same dose delivered IN produced no change. RO studies using PET 
were conducted with equipotent dose of NLX (0.032 mg/kg) given IN and IV. These 
studies showed that IV administration resulted in greater blocking of [11C]CFN binding, 
however the differences between routes were relatively small, and did not result in 
significant behavioral changes under these conditions.  
 Drug potency and bioavailability varies as function of route of administration. The 
extent to which pharmacodynamics are altered by changing the route of delivery 
depends on the drugs physiochemical properties, and other variables that govern 
absorption, distribution, and metabolism. For example, the peptide DAMGO, a highly 
potent and efficacious µ-opioid receptor agonist, produces no measurable behavioral 
effects when given systemically, but following intrathecal (IT) administration, it produces 
antinociception, itch, and respiratory depression (Ko et al., 1998; Ko et al., 2006). 
Morphine produces antinociception when administered IV, IN, SC, and PO (orally), but 
the dose that produces a given level of effect varies considerably among routes 
(Grassin-Delyle et al., 2012). In rhesus monkeys, IT morphine produced maximum 
antinociception at a dose of 0.03 mg, however when given IM, doses between 3.2 and 
5.6 mg/kg are required for the same level of effect (Lee et al., 2007; Maguire and 
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France, 2014). The onset and duration of action, as well as the spectrum of on-target 
and off-target side effects, may also vary with the route of administration. For example, 
compared to systemic administration, IT morphine has a longer duration of action, and 
was reported to produce significantly more pruritus (Ko et al., 2004).  
 Naloxone, which is normally administered IM or IV, is frequently given off-label 
through the IN route to reverse opioid toxicity. Results from studies conducted in 
humans have shown that IN NLX can be effectively used to reverse opioid toxicity. 
However, questions persist regarding the onset of action, duration of effect, and the 
potency of IN naloxone, as well as its overall effectiveness relative to other routes. In 
the present study, IN and IV NLX were found to be equipotent in reversing the 
antinociceptive effects produced with IV fentanyl. Doses of NLX that antagonized 
fentanyl were similar to those used in published studies to block different µ-agonist 
effects in monkeys. For example, the antinociceptive effects of IT morphine (1 mg) were 
blocked with IM NLX 0.03-0.1 mg/kg in a shock titration paradigm (Yaksh, 1983). In 
morphine-dependent rhesus monkeys trained to discriminate 0.032 mg/kg of naltrexone, 
NLX 0.01-0.032 mg/kg SC completely substituted for a naltrexone stimulus, and 
likewise, NLX 0.01 mg/kg SC was found to precipitate withdrawal in monkeys that were 
made physically dependent on morphine (Gauthier and France, 1999; Valentino et al., 
1983).  
 It has been suggested that IN administration results in direct absorption to the 
CNS (Dhuria et al., 2010), and some studies have attributed the rapid onset of action 
seen with IN NLX to this pattern of absorption (Sabzghabaee et al., 2014). Typically, 
drugs that produce their effects in the CNS, are active at very small doses when 
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administered centrally. Given that the potency of IN and IV NLX were equivalent, and 
that a similar range of doses administered systemically have been shown to block 
various µ-agonist effects, it is unlikely that IN administration in this study resulted in the 
direct absorption to the CNS. 
 The level of a receptor-mediated response to a drug stimulus is proportional to 
the percentage of receptors occupied. At the whole organism level, dose is one of the 
key variables that controls RO, and the effect produced with a given dose can vary 
depending on the route of administration. There are no published studies evaluating the 
percentage of receptors that need to be occupied by naloxone in order to block a 
specific µ-agonist effect. In fact, few studies have investigated the pharmacokinetics of 
naloxone given by different of routes of administration in any context, or have correlated 
these results with behavioral end points.  
 In humans, the bioavailability of IN NLX was found to be 4% of IV administration 
(Dowling et al., 2008). This led to the supposition that the clinical response to IN 
naloxone might be less than that produced through other routes of administration. 
However, studies with IN nicotine and fentanyl have demonstrated that venous blood 
sampling, the method often used for PK evaluation, may underestimate the 
bioavailability of intranasally administered drugs (Gourlay and Benowitz, 1997; Guthrie 
et al., 1999; Moksnes et al., 2008). In a direct comparison of IV and IN nicotine, it was 
found that both routes of administration produced comparable bioavailability in the 
arterial circulation, and that drug concentration in this compartment more accurately 
predicted pharmacodynamic endpoints (Gourlay and Benowitz, 1997).  
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 Since it is possible that the same level of behavioral effect can be produced with 
different receptor occupancies, particularly for a response where there is a receptor 
reserve, it was important to determine if equipotent doses of NLX given by different 
routes of administration were equivalent on a receptor basis. This would be particularly 
relevant in the context of evaluating IN and IV NLX under conditions where the 
percentage of agonist occupancy is relatively large (i.e. opioid overdose). IN and IV NLX 
were found in PET analysis to produce similar receptor occupancies although this 
varied slightly depending on the brain region. For example, in the pons, which controls 
aspects of the respiratory drive, NLX occupied 65% of the receptors available for 
binding following IN administration, whereas it occupied 75% of the available receptors 
following IV administration. However, in the parietal cortex, there was no difference in 
receptor occupancy between IV and IN administration. Overall, receptor occupancy with 
IV NLX was consistently larger than the occupancy produce with IN administration, but 
these differences were not sufficient to produce changes in behavior. These results 
demonstrate that IN and IV naloxone are nearly equivalent in two important 
pharmacodynamic dimensions that have clinical relevance.  
 This study had several limitations. Because the monkeys needed to receive 
anesthesia for IN administration it was not feasible to study whether the onset of action 
for NLX differed as a function of route. Since time is a critical factor in an opioid 
overdose this would have been valuable information. Clinically NLX is not administered 
to block the analgesic effects of opioid agonists, but to reverse opioid-induced 
respiratory depression. Although the dose of IV fentanyl used in this experiment was not 
toxic, IV fentanyl (0.018 mg/kg) has been shown to reduce the amount of respired air by 
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40% in rhesus monkeys. Increasing the dose of fentanyl by as little as a quarter log unit 
from this maximally effective dose has been reported to produce respiratory arrest in 
some animals (Ko et al., 2002; Saccone et al., unpublished observations). Although not 
a perfect proxy for measures of toxicity, the ability of NLX to reverse opioid action in this 
study was challenged by assessing behavior that is associated with relatively large-
dose effects.  
 The modified nasal atomizer, which was adapted to fit into the monkey’s nostril, 
was likely inserted further into the nose than would be possible had the Styrofoam 
stopper been in place. Some have argued that more posterior drug deposition, in 
proximity to the superior turbinate and cribriform plate, may enhance direct CNS 
absorption. However, it was found that the potency of IN NLX to block the effects of 
fentanyl was consistent with other routes of administration that result in systemic drug 
absorption. Lastly, in an opioid overdose situation the agonist would be on board prior to 
the administration of naloxone, while in the present study NLX was administered prior to 
fentanyl. Pharmacologically, however, this should not make a difference in terms of 
measuring antagonist potency because almost all clinically used opioids are competitive 
with the receptor.  
 For IN administration, we elected to use parameters that would optimize IN drug 
delivery based on previous literature (Dhuria et al., 2010; Fortuna et al., 2014; Grassin-
Delyle et al., 2012; Landis et al., 2012). The volume of administration was kept between 
50-200 µl in a single nostril, and the concentration of NLX varied between 1 - 2 mg/ml. 
Large solution volumes and low drug concentration have been reported to reduce the 
bioavailability and effectiveness of drugs given IN. To date, IN NLX has been given in 
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larger volumes, typically 1 ml of 1 mg/ml solution. Thus, the extent to which these 
findings would be generalizable to the current clinical standards is unclear. More 
research is needed to understand how the effects of drugs administered IN are altered 
by solution volume and dose.        
 Overall, this study successfully established the first model to measure the 
behavioral effects of IN delivered opioid antagonists, and to evaluate receptor 
occupancy with PET following IN delivery. This route of administration remains 
promising for medication development and for improving treatment with currently used 
drugs.  
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Figure 3.1 Time course of intranasal and intravenous naloxone antagonism of 
fentanyl-induced antinociception. Time course data for the effects of NLX (0.0032-0.032 
mg/kg) administered IN (A) and IV (B) to block fentanyl-induced increases in tail-withdrawal 
latency in rhesus monkeys (n=3). Data are presented as the mean (± SEM) maximum 
percent effect and plotted as a function of time. Abscissae: Time in minutes (min). 
Ordinates: Tail-withdrawal latency presented as maximum percent effect (MPE).  
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FIgure 3.2  The effects of intranasal and intranvenous naloxone on tail-withdrawal 
latency averaged across the 90-minute session. Mean (±SEM) tail-withdrawal latency 
from 50° C water averaged across the 90-minute session produced with IV fentanyl alone 
and in the presence of IN and IV NLX (0.0032-0.032 mg/kg). Abscissae: IV fentanyl (0.018 
mg/kg) alone (F) and doses of naloxone in milligrams per kilogram. Ordinates: Tail-
withdrawal latency presented as maximum percent effect (MPE). Significant differences 
between fentanyl alone and different doses of naloxone are indicated by, * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001 
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Figure 3.3 Brain tissue time-radioactivity curves for [11C]carfentanil alone, and in the 
presence of intranasal and intravenous naloxone. Brain tissue time-radioactivity curves 
(TACs) for selected brain regions.  TACs from [11C]CFN alone (top panel) and in the 
presence of NLX 0.032 mg/kg delivered IN (middle panel) and IV (bottom panel). Middle 
panel presents the TACs following IN NLX (0.032 mg/kg) administration. Abscissae: Time in 
minutes (min). Ordinates: Measures of radioactivity in nano-Curi's per cubic centimeter per 
milli-Curi's injected. 
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Figure 3.4 Receptor occupancy estimates for intranasal and intravenous  
Naloxone. Percent receptor availability in selected brain regions following IN and IV NLX 
(0.032 mg/kg). RO was estimated as the ratio of DVR values obtained from PET images 
with [11C]CFN alone relative to the DVRs calculated after NLX blocking experiments. 
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Figure 3.5 microPET Images. Representative coronal microPET images of [11C]CFN 
alone (left) and following blocking studies with IN (middle) and IV (right) NLX (0.032 mg/kg). 
All images are summed images 0–60 min following IV injection of the radiotracer. 
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CHAPTER FIVE 
GENERAL DISCUSSION 
 
 
 The introduction to this thesis argued that the primary concern regarding the use 
of opioids was balancing the legitimate therapeutic purpose of these medicines with 
their unwanted effects. Optimizing the medical use of opioids is to align the desired 
effect (onset and duration of action; magnitude of effect; mode of action) with the goals 
of therapy (Inturrisi, 2002). The unwanted effects of opioids that are related to drug 
abuse and addiction, and those that are therapeutically complicating, such as 
constipation, respiratory depression, and itch, all serve to interfere with either: a 
practitioners willingness to prescribe these medicines, the patients willingness to initiate 
or continue therapy, and/or for the drugs themselves to be effective (Jamison et al., 
2014; Labianca et al., 2012; McNicol, 2008). As a result, continuing research efforts aim 
to identify new targets for pain control as well as methods to optimize the way opioids 
are clinically used. 
 The work presented here addressed two distinct strategies that have in common 
the goal of improving opioid therapy. In the first chapter, the behavioral pharmacology of 
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a new opioid target for pain control, NOPr, was investigated. The next two chapters 
focused on developing a procedure to measure the behavioral effects of intranasally 
administered opioids in rhesus monkeys. The general conclusions of this thesis were as 
follows.  
 The NOPr agonist Ro 64-6198 produced discriminative stimulus effects that are 
distinct from agonists at other opioid receptors, and may be similar to diazepam, in 
rhesus monkeys. In contrast to previous studies, Ro 64-6198 did not produce 
antinociception in the warm water tail-withdrawal assay indicating that the analgesic 
effects of this drug may be more variable than previously described.  
 Additionally, this thesis established a procedure to measure the ability of IN 
opioids to modify the effects of warm water on tail-withdrawal behavior in rhesus 
monkeys. The opioid agonists fentanyl and buprenorphine were shown to produce 
dose-dependent increases in tail-withdrawal latency following IN delivery. When 
compared to IM administration, there was a trend for fentanyl and buprenorphine to 
produce a faster onset of action, and larger increases in tail-withdrawal latency with 
smaller doses. This study also established preliminary evidence for the analgesic 
effects of an opioid peptide, MMP 2200, given intranasally in measures of capsaicin-
induced allodynia. 
 Opioid antagonists also play a vital role in medicine, and this procedure was 
modified to study IN NLX in a manner that has become of public health relevance. A 
study was conducted comparing the potency and duration of effect of IV and IN NLX to 
block the antinociceptive effects of IV fentanyl. Additionally, brain µ-receptor occupancy 
was measured using [11C]CFN and PET imaging following NLX given through both 
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routes of administration. These studies showed that IV and IN NLX were equipotent in 
antagonizing fentanyl-induced antinociception, and that these effects were produced 
with comparable receptor occupancy.  
 
Characterizing the discriminative stimulus effects of Ro 64-6198 
 This was the first study to train a NOPr agonist as a discriminative stimulus in 
rhesus monkeys. Previous work demonstrated that Ro 64-6198 produced discriminative 
stimulus effects in rats (Recker and Higgins, 2004). In general, there was agreement 
between the results from the discrimination studies in rats and rhesus monkeys with 
regard to the non-overlapping stimulus effects of selective opioid agonists. However, the 
question of whether Ro 64-6198 produced interoceptive effects that were similar to 
drugs from other pharmacological classes was left unaddressed in the rat study. 
Substitution experiments were performed with the non-opioid drugs PCP, 
chlorpromazine, and diazepam in monkeys trained to discriminate Ro 64-6198. 
Interestingly, diazepam was found to produce partial generalization to a Ro 64-6198 
stimulus. Follow-up experiments revealed that diazepam and Ro 64-6198 produced 
common interoceptive effects that were likely mediated by two distinct receptors. 
 The generalizability of this finding to other benzodiazepines, or drugs acting at 
different sites on GABAA, was not evaluated in the current study, and is a noted 
weakness. Substitution studies with drugs such as muscimol (a direct acting GABAA 
agonist), midazolam (positive allosteric modulator at the BZD binding site), and 
pregnanolone (positive allosteric modulator at the neuroactive steroid site) would extend 
the current findings to drugs that stimulate the receptor through different mechanisms. It 
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would also be interesting to learn whether monkeys trained to discriminate diazepam 
generalized to Ro 64-6198. Nevertheless, this was an interesting finding given that Ro 
64-6198 and other NOPr agonists produce anxiolytic-like behavior in rodents. Data from 
this study support the notion that NOPr agonists may be good anxiolytics to the extent 
that the therapeutic actions of benzodiazepines are related to their interoceptive effects. 
 The most surprising result from studies with Ro 64-6198 was the lack of 
antinociceptive effects particularly given the data from previous work showing that Ro 
64-6198 produced analgesia that was comparable to alfentanil (Ko et al., 2009). This 
study evaluated doses ten times larger than those used in studies where Ro 64-6198 
was antinociceptive, and a positive effect was found in only one animal at the largest 
dose tested (0.32 mg/kg). A range of doses (0.0032- 0.32 mg/kg) was tested in eight 
different animals throughout the course of these studies. Experiments began in three 
subjects using doses between 0.003 - 0.032 mg/kg. When those doses failed to 
produce an increase in tail-withdrawal latency, the dose range was increased by a ½ log 
unit, and then another ½ log unit after no positive effects were again found on tail-
withdrawal latency. Experiments continued in this fashion with different animals for the 
next several months until we reached the solubility limit of Ro 64-6198. For the final 
series of experiments, doses between 0.032-0.32 mg/kg were administered to four 
animals.  
 Given that we tested a dose range over two log units, it is unlikely that the doses 
used in the final series of experiments were on the descending limb of a biphasic dose-
effect curve. It should also be noted that the potency of other drugs to produce 
antinociception used throughout this thesis are in agreement with the published 
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literature. The reasons for the discrepancy remain unclear, and reemphasize the need 
to replicate research across laboratories.  
 Although these data question the strategy of developing selective NOPr agonists 
for pain control, they may have positive implications for the development of bifunctional 
or mixed acting agonists (ligands designed to stimulate more than one receptor) at 
NOPr and µ-receptor. There are instances where opioids may be given in combination 
with benzodiazepines for the treatment of comorbid conditions associated with acute 
and chronic pain (Hawkins et al., 2015; Nielsen et al., 2015). At the clinical level, 
patients with chronic pain display a complex set of psychological and physical sequelae 
that often require multiple treatment modalities (Dale and Stacey, 2016; Kayhan et al., 
2015). The co-administration of opioids and benzodiazepines has been shown to have 
additive or synergistic effects on respiratory depression, sedation, and measures of 
abuse liability, which results in increased morbidity for those who use these drugs in 
combination (Giummarra et al., 2015). Benzodiazepines alone have a risk of abuse, and 
they are also capable of producing physical dependence and an abstinence syndrome 
that may be life threatening (Woods et al., 1992). Bifunctional NOPr/µ-agonists have 
been evaluated in preclinical models of chronic pain, and were generally shown to be 
effective (Khroyan et al., 2009; Schroder et al., 2014; Sobczak et al., 2014). Should a 
benzodiazepine-like component be identified in other NOPr agonists, it is possible that 
bifunctional ligands at NOPr and the µ-receptor may reduce the need for combination 
therapy with these drugs, as well as address some of the psychological dimensions that 
are associated with chronic pain.  
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Intranasal drug administration: opioid agonists 
 The benefits of IN administration include a rapid onset of action, the ability to 
administer drugs parenterally without the use of a needle, and the avoidance of GI and 
hepatic first-pass metabolism (Fortuna et al., 2014). Given these attributes, it is also 
possible that IN administration may result in the more routine development and use of 
peptides and proteins as therapeutics (these chemical entities are not easily adaptable 
to oral administration). The purpose of the first set of experiments was to develop a 
procedure for measuring the antinociceptive effects of IN opioid agonists in rhesus 
monkeys. Most of the preclinical work on IN drug administration has taken place in rats 
even though there are anatomical and physiological differences between rodents and 
primates that suggest the latter may have more translational relevance. The lack of 
good animal models that predict the effects of intranasally administered drugs in man 
has been cited as a reason why more therapeutics are not developed for this route of 
administration (Landis et al., 2012). Lastly, regardless of the models particular 
translational relevance, the importance of measuring the effects of drugs in different 
preparations is well recognized.  
 Initial experiments to characterize the pharmacodynamics of IN administration 
compared to IM delivery, and to validate the procedure across different pain modalities, 
were performed with a diverse set of opioid agonists: fentanyl, buprenorphine and the 
opioid peptide, MMP 2200. Experiments with IN fentanyl administration produced dose-
dependent increases in tail-withdrawal latency, and consistent with the published 
literature, was found to be a full agonist under these conditions. At smaller doses, there 
was a trend for fentanyl delivered IN to produce larger increases in tail-withdrawal 
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latency, and for these effects to have a quicker onset of action and a longer duration of 
effect compared to IM administration. For example, IN fentanyl 0.01 and 0.018 mg/kg 
produced significant increases in tail-withdrawal latency across the 120-minute session, 
while the same doses of IM fentanyl did not (although IM fentanyl 0.018 mg/kg 
produced similar peak effects). The effects of IN fentanyl 0.018 mg/kg on tail-withdrawal 
latency were apparent immediately following recovery from propofol anesthesia, and 
remained above saline levels for 80 minutes. IM fentanyl 0.018 mg/kg increased in tail-
withdrawal latency beginning at 20 minutes, and these effects had largely dissipated 
before the 60-minute time point. Fentanyl 0.01 mg/kg delivered IM was not behaviorally 
active. 
  Buprenorphine’s effect on antinociception did not significantly differ between 
active doses or routes of administration. The observation that a relatively wide range 
buprenorphine doses (0.1 -1.0 mg/kg) produced increases in tail-withdrawal latency that 
plateaued between 66-80% MPE strongly suggested that buprenorphine was a partial 
agonist in this procedure. Confirmation of this partial agonist effect could have been 
obtained by pretreating monkeys with buprenorphine prior to measuring the 
antinociceptive effects of fentanyl, however buprenorphine’s identification as a partial 
agonist has already been well characterized in the literature (Cowan et al., 1977a; 
Cowan et al., 1977b; Walker et al., 1995). At smaller doses, there was a trend for IN 
buprenorphine to have a faster onset of action. IN buprenorphine (0.1 mg/kg) increased 
tail-withdrawal latency to 50% MPE within the first 20 min following recovery from 
anesthesia, while doses of IM buprenorphine did not produce increases of this 
magnitude until the 60-minute time point.  
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 The conclusions regarding IN and IM administration were limited to opioids with 
high lipophilicity, which in general have an easier time crossing membranes and 
entering the CNS. Future studies may wish to investigate how the pharmacodynamics 
of IN opioids vary as a function of different physiochemical properties, such as 
lipophilicity, molecular weight, or degree of ionization. Additionally, changes in potency 
between routes of administration may have been more clearly differentiated using 
thermal stimuli of different intensities. In the warm water tail-withdrawal procedure, 
agonist potency and efficacy has been shown to depend on the water temperature 
(Walker et al., 1998). For fentanyl, increasing the temperature above 50° C may have 
more clearly separated the effect of route on tail-withdrawal latency, while lowering the 
temperature for buprenorphine below 50° C may have allowed more sensitivity to detect 
an effect between large and small doses by either route of administration.  
 The aim of the last experiment in this chapter was to apply this procedure to a 
different pain modality (capsaicin-induced allodynia), and to highlight one of the 
potential advantages of IN administration: the use of peptides as therapeutics. MMP 
2200 is a mixed µ/δ agonist that was previously shown not to be active in measures of 
acute thermal nociception, but was able to reverse allodynia in rhesus monkeys (Do 
Carmo et al., 2008). The data from this experiment was limited because it was 
determined that over time the monkeys became desensitized to the effects of capsaicin. 
However, using data gathered only from experiments where the ability of capsaicin to 
produce allodynia was verified, MMP 2200 1 and 3 mg/kg were capable of reversing 
allodynia in 2/3 animals. The reasons for the development of desensitization to 
capsaicin are unclear, however there are a few noteworthy differences between the 
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current study and previous work. The present experiment used doses of capsaicin that 
were larger than those used in other studies, and propofol was given in order to 
administer MMP 2200 intranasally. There are reported drug interaction between the 
propofol and capsaicin, which makes an idiosyncratic drug interaction plausible. It would 
be interesting to learn if desensitization to experimental allodynia can be seen with 
different anesthetics and chemical stimuli.  
 
Comparison of intranasal and intravenous naloxone in behavioral measures and 
receptor occupancy 
 The investigation of intranasal opioid administration was extended to opioid 
antagonists as well. There were two reasons for its inclusion. First, opioid antagonists 
have a vital role in therapeutics. They are FDA-approved to treat opioid dependence, 
and are used to reverse opioid toxicity (Comer et al., 2006; Wermeling, 2013). 
Secondly, the use of IN NLX has been a critical factor in the decision to increase the 
distribution/availability of naloxone as a means to combat opioid overdose (Rando et al., 
2015). These programs have extended naloxone access to more first responders (such 
as police officers) as well as opioid abusers, and the people who are close to them (Ray 
et al., 2015). There have even been documented instances of IN self-administration of 
naloxone (Green et al., 2014).  
 Although IN administration is gaining acceptance, and studies conducted in the 
field have indicated that it is effective in reversing opioid overdose in humans, there are 
still unresolved pharmacological questions regarding IN administration (i.e. potency, 
duration of effect, generally efficacy compared to other routes of administration). There 
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have been no laboratory controlled studies evaluating the potency of NLX to antagonize 
the effects of opioid agonists as a function of route of administration, nor has there been 
an assessment of how this translates into receptor occupancy at the µ-opioid receptor.  
 Overall, IN and IV NLX were equipotent in antagonizing the effects of fentanyl in 
this procedure, however there were some notable differences between the routes of 
administration. At the largest dose tested (NLX 0.032 mg/kg), there was no apparent 
difference between routes of administration. There was a trend for IV NLX to produce a 
greater decrease in fentanyl-induced antinociception, particularly at lower doses (0.0032 
mg/kg and 0.01 mg/kg). IN NLX 0.0032 mg/kg produced only very slight decreases in 
tail-withdrawal latency following fentanyl, and these effects were not significantly 
different relative to fentanyl alone. In contrast, IV NLX (0.0032 mg/kg) consistently 
produced effects that were numerically smaller at almost every time point both 
compared to fentanyl alone, and to IN NLX. These effects were found to be significantly 
different from fentanyl alone, but not different from the same dose of NLX given IN.  
  The PET studies revealed that IN and IV NLX administration resulted in similar 
receptor occupancies. Brain tissue time-radioactivity curves demonstrated that blocking 
studies with NLX given by either route produced more rapid clearance of [11C]CFN. This 
was more pronounced for IV NLX where the peak uptake of [11C]CFN in all brain 
regions was suppressed compared to the radiotracer alone, and the IN blocking studies. 
A Logan analysis showed a trend for IV NLX 0.032 mg/kg to produce slightly greater RO 
when compared to IN NLX, but this varied by brain region. The largest differences were 
noted in the striatum, and temporal cortex, while there appeared to be no difference in 
parietal cortex between routes of administration. The pons, a brain region that is critical 
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for controlling respiratory drive, showed only a modest difference between routes of 
administration (IN: 66% vs IV: 75%). At least with high doses of NLX, there appeared to 
be good concordance between the PET and studies of antinociception. The findings of 
this study offer support to the clinical research that has argued for IN NLX as an 
alternative first line treatment for opioid overdose. 
  Taken together, the conclusions from this thesis support the need for further 
research on the potential for NOPr agonists to be the illusive Holy Grail. The analgesic 
effects of this compound were not as reliable as previously reported, and additional 
work should be done to learn to more about the qualitative aspects of the NOPr-
mediated stimulus, such as whether or not it may be aversive. On the other hand, the 
establishment of a procedure to measure the effects of IN opioid administration opens 
the possibility that new opioid drugs can be developed utilizing his route of 
administration which may have a positive implication for pain control, and the other 
therapeutic uses of opioids.  
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